

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005004

International filing date: 26 November 2004 (26.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0327524.5
Filing date: 26 November 2003 (26.11.2003)

Date of receipt at the International Bureau: 04 March 2005 (04.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT/GB2004/005004



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 21 December 2004





Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

SJK/BP6182554

2. Patent application number

(The Patent Office will fill this part in)

26 NOV 2003

0327524.5

3. Full name, address and postcode of the or of each applicant (underline all surnames)

~~University of Glasgow~~
~~10 The Square~~
~~Glasgow~~
~~G12 8QQ~~

Patents ADP number (if you know it)

00773846003

If the applicant is a corporate body, give the country/state of its incorporation

THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW
GILBERT SCOTT BUILDING
GB UNIVERSITY AVENUE
GLASGOW G12 8QQ

4. Title of the invention

Heterocyclic Aromatic Compounds

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 89

Claim(s) 0

Abstract 0 DL

Drawing(s) 3 + 3

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for a preliminary examination and search (Patents Form 9/77) 0

Request for a substantive examination (Patents Form 10/77) 0

Any other documents (please specify) 0

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Markus Elm

Date 24 November 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Simon Kiddle
+44 117 926 6411

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Heterocyclic Aromatic Compounds

Field of the Invention

5 The present invention relates to heterocyclic aromatic compounds, and more particularly to phenanthridinium derivatives such as dihydro-imidazo-phenanthridinium (DIP) compounds. The present invention further relates to methods of making these compounds and their uses, in particular as DNA binding agents and as pharmaceuticals.

10

Background of the Invention

Heterocyclic rings are present as fundamental components in the skeletons of more than half of the biologically active compounds produced by nature. With this in mind, there have been great efforts to discover and optimise new reactions that will facilitate the construction of heterocycles, especially when the methodology leads to a new type of N-based heterocycle. A facile route to a new family of heterocycles opens the possibility of finding new types of biologically active units that can be used in the generation of libraries of compounds, or for use in the development of new methodologies to be applied in organic synthesis.

25 Yamazaki et al (J. Heterocyclic Chem., 16: 517-525, 1979) discloses the synthesis of Dihydro-Benzo[f]Imidazo[1,2-a]quinoline in three steps with an overall yield of 40%. The compounds produced also have the disadvantage that they are not functionalised.

30

Koyama et al (Chem. Pharm. Bull., 23(9):2015-2018, 1975) discloses the synthesis of dihydro-imidazo-benzo[h]quinazolinium in three steps with one example of substitution at one position on the molecule.

Preston et al (J. Med. Chem., 471-480, 1964) discloses the synthesis of dihydro-imidazo-quinolinium in three steps at very low yield (10%).

5

Osbond (J. Chem. Soc., 1853-1856, 1950) also discloses the synthesis of dihydro-imidazo-quinolinium in four steps.

Summary of the Invention

10 Broadly, the present invention concerns new classes of heterocyclic aromatic cationic compounds, and in particular new classes of phenanthridinium derivatives, most notably dihydro-imidazo-phenanthridinium (DIP) compounds. These findings are based on the reaction of
15 the middle **b** ring of a phenanthridinium core with primary amines to form DIP compounds (Formula A) or secondary amines to form 2-aminoalkyl phenanthridinium derivatives (Formula B). These reactions can also be applied to other classes of starting compounds which comprise a 6-membered
20 ring aromatic heterocycle having a ring nitrogen and at least one alpha hydrogen atom which can be reacted with a primary or secondary amine.

Moreover, analogous reactions can be carried to produce
25 dihydro-thiazoles, e.g. by reaction with a sulphate such as sodium sulphate Na_2S , and to produce dihydro-oxazoles, e.g. by reaction with a hydroxide such as KOH.

Typically, the chemistry disclosed herein has the
30 advantage that is amenable to scaling up to large scale production as it does not involve any particularly hazardous reaction procedures. Further, the one pot reactions disclosed herein can be carried out at room temperature and usually take less than 12 hours, with the


result that the energetic cost of the industrialization process may be quite low.

5 In general, N-based heteroaromatic cations are highly
interesting compounds due to their reactivity and
biological properties. For instance, molecules containing
a phenanthridinium core are one important subset of
heteroaromatic cations with applications as drugs
(topoisomerase inhibitors and DNA targeting agents), dyes
10 and probes due to their high affinity for DNA. Moreover,
a simple purification method (i.e. filtration of the
reaction medium and wash) may make them very good
candidates for combinatorial chemistry. Finally, because
of the highly effective hydride transfer of the
15 intermediaries in forming the phenanthridinium
derivatives, there may be applications in non-enzymatic
redox transformation, e.g. the reduction of ketones,
sulfonates, arenediazoniums and aldehydes.

20 A first class of compounds represented herein by Formula A
are based on the ring extension of the heteroaromatic
middle **b** ring of the phenanthridinium core, typically
forming a new 5-8 membered ring, and more preferably a
five or six membered ring. The new ring may comprise a
25 dihydro-imidazolium, a dihydro-thiazolium, a dihydro-
oxazolium moiety or a tetrahydro-pyrimidinium moiety,
depending on whether the reaction is carried out with a
primary amines or a sulphate or hydroxide compound to
introduce a nitrogen, a sulphur or an oxygen heteroatom
30 respectively. A second class of compounds represented by
Formula B are based on the reaction of the heteroaromatic
middle **b** ring of the phenanthridinium core with secondary
amines, followed by an intramolecular rearrangement
process.

In other aspects, the present invention provides methods for synthesising the compounds of the invention. The inventors have also elucidated the mechanisms of these reactions which are unprecedented. The mechanisms provide a basis for extending the specific reaction described herein to the synthesis of other types of heterocyclic aromatic cationic compounds.

Accordingly, in a first aspect, the present invention provides a compound represented by Formula A:



wherein:

$n = 0, 1, 2$ or 3 such that:

when $n = 0$, the substituents R_{17} and R_{18} and the carbon atom to which they are bonded are not present; and

when n is $1, 2$ or 3 , the substituents R_{17} and R_{18} present on the respective carbon atom(s) may be the same or different and are independently selected from hydrogen or a substituent as defined herein;

W is C or N , such that when W is N , R_4 is a lone pair of electrons;

Y is selected from N, O or S , such that:

when Y is O or S, R₁ is a lone pair of electrons; and

when Y is N, R₁ is selected from:

5 hydrogen,

C₁₋₇alkyl, optionally substituted with one or more
substituents as defined herein, e.g. a group which is a
substituted or unsubstituted C₁₋₇alkyl, C₁₋₇haloalkyl,
10 C₁₋₇hydroxyalkyl, C₁₋₇carboxyalkyl, C₁₋₇aminoalkyl group,

C₁₋₇cycloalkyl, optionally substituted with one or more
substituents as defined herein,

15 C₁₋₇cycloalkyl-C₁₋₇alkyl, optionally substituted with one or
more substituents as defined herein,

C₅₋₂₀aryl, optionally substituted with one or more
substituents as defined herein, e.g. C₅₋₂₀carboaryl or
20 C₅₋₂₀heteroaryl,

C₁₋₇alkyl-C₅₋₂₀aryl and C₅₋₂₀haloaryl, optionally substituted
with one or more substituents as defined herein,

25 C₅₋₂₀aryl-C₁₋₇alkyl, optionally substituted with one or more
substituents as defined herein,

C₃₋₂₀heterocyclyl, optionally substituted with one or more
substituents as defined herein,

30

or a linking group to form a multimeric compound in which
a plurality of compounds represented by Formula A and/or
Formula B are covalently bonded together, e.g. via their

respective R_1 substituents (Formula A) or via their R_6 or R_7 substituents (Formula B) or via a spacer group;

5 independently R_2 and R_3 and/or R_4 and R_5 together can form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents as defined herein, or R_2 , R_3 , R_4 and R_5 are independently selected from an aromatic substituent as defined herein;

10

R_6 and R_7 are independently selected from hydrogen or independently or together can be a substituent as defined herein;

15 R_8 and R_9 are independently selected from hydrogen or independently or together can be a substituent as defined herein;

wherein when R_{17} and R_{18} are present, they are
20 independently selected from hydrogen or independently or together can be a substituent as defined herein; and

one of the substituents R_6 and R_7 which is present on the carbon atom at the alpha position to the aromatic ring can
25 form a double bond with one of the substituents R_8 and R_9 or R_{17} and R_{18} which is present on the carbon atom at the beta position to the aromatic ring; and


X^- is an anionic moiety, such as halogen (e.g. Cl^- , Br^- or
30 I^-), tosylate or mesylate.

In this aspect of the invention, preferred compounds represented by Formula A comprise a 5 or 6 membered ring extension, e.g. as produced when $n = 0$ or 1 respectively.

Alternatively or additionally, further preferred compounds are provided when W is a carbon atom.

5 Other preferred compounds of Formula A are provided when the Y substituent is N and/or $n = 0$, so that the substituents R_{17} and R_{18} and the carbon atom to which they are bonded are not present and a 5-membered ring is formed.

10 In a further aspect, the present invention provides a compound represented by Formula Ai:



wherein:

15

R_1 is selected from:

hydrogen,

20 C_{1-7} alkyl optionally substituted with one or more substituents as defined herein, e.g. a group which is a substituted or unsubstituted C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl group, C_{1-7} cycloalkyl, optionally substituted with one or more
25 substituents as defined herein,

C_{1-7} cycloalkyl- C_{1-7} alkyl, optionally substituted with one or more substituents as defined herein,

C₅₋₂₀aryl, optionally substituted with one or more substituents as defined herein, e.g. C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl,

- 5 C₁₋₇alkyl-C₅₋₂₀aryl and C₅₋₂₀haloaryl, optionally substituted with one or more substituents as defined herein,

C₅₋₂₀aryl-C₁₋₇alkyl, optionally substituted with one or more substituents as defined herein,

10

C₃₋₂₀heterocyclyl, optionally substituted with one or more substituents as defined herein,

- 15 or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A and/or Formula B are covalently bonded together, e.g. via their respective R₁ substituents (Formula A) or via their R₆ or R₇ substituents (Formula B) or via a spacer group;

- 20 independently R₂ and R₃ and/or R₄ and R₅ together can form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents as defined herein, or R₂, R₃, R₄ and R₅ are independently selected from an aromatic substituent as
25 defined herein;

R₆ and R₇ are independently selected from hydrogen or independently or together can be a substituent as defined herein;


30

R₈ and R₉ are independently selected from hydrogen or independently or together can be substituent as defined herein;

wherein one of R₆ and R₇ and one of R₈ and R₉ can together form a double bond; and,

X⁻ is an anionic moiety, such as halogen (e.g. Cl⁻, Br⁻ or I⁻), tosylate or mesylate.

In a further aspect, the present invention provides a compound represented by Formula Aii:



wherein:

R₁ is selected from:

hydrogen,

C₁₋₇alkyl optionally substituted with one or more substituents as defined herein, e.g. a group which is a substituted or unsubstituted C₁₋₇alkyl, C₁₋₇haloalkyl, C₁₋₇hydroxyalkyl, C₁₋₇carboxyalkyl, C₁₋₇aminoalkyl group,

~~C₁₋₇cycloalkyl, optionally substituted with one or more substituents as defined herein,~~

C₁₋₇cycloalkyl-C₁₋₇alkyl, optionally substituted with one or more substituents as defined herein,

C₅₋₂₀aryl, optionally substituted with one or more substituents as defined herein, e.g. C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl,

- 5 C₁₋₇alkyl-C₅₋₂₀aryl and C₅₋₂₀haloaryl, optionally substituted with one or more substituents as defined herein,

C₅₋₂₀aryl-C₁₋₇alkyl, optionally substituted with one or more substituents as defined herein,

10

C₃₋₂₀heterocyclyl, optionally substituted with one or more substituents as defined herein,

- or a linking group to form a multimeric compound in which
15 a plurality of compounds represented by Formula A and/or Formula B are covalently bonded together, e.g. via their respective R₁ substituents (Formula A) or via their R₆ or R₇ substituents (Formula B) or via a spacer group;

- 20 R₆ and R₇ are independently selected from hydrogen or independently or together can be a substituent as defined herein;

- R₈ and R₉ are independently selected from hydrogen or,
25 independently or together can be substituent as defined herein;

wherein one of R₆ and R₇ and one of R₈ and R₉ can together form a double bond; and

30

R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅ and R₁₆ are independently selected from hydrogen or an aromatic substituent as defined herein; and

X⁻ is an anionic moiety, such as halogen (e.g. Cl⁻, Br⁻ or I⁻), tosylate or mesylate.

5 In the present invention, preferred examples of linking groups are C₁₋₇alk-di-yl, piperazin-di-yl, (N,N-C₁₋₇dialkylene)C₁₋₇alkylene amine bonding to the R₁ group of a compound of Formula A or the R₆ and/or R₇ group of a compound of Formula B.

10 Examples of compounds represented by Formula A, Ai and Aii are set out below and include the following compounds:

1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium bromide;

15 1-(2-Hydroxy-ethyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide;

2,3-Dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide;

1-Isopropyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide;

20 1-Cyclopropyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide;

1-(4-Methoxy-phenyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide;

25 1-Phenyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide; and

1-paramethoxyaniline-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide.

1-Methoxycarbonylmethyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide.

30 1-(1-Methoxycarbonyl-2-phenyl-ethyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide.

1-Benzyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide.


1-(2-Mercapto-ethyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide.

3-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-a]quinolin-10-ylum bromide.

5 1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[2,1-a]isoquinolin-4-ylum bromide.

1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-a]pyridin-4-ylum bromide.

10 In a further aspect, the present invention provides a compound represented by Formula B:



wherein:

15 n is 2 to 5, more preferably 2-3, and most preferably 2;

R₁ is hydrogen or an aromatic substituent as defined herein;

20 independently R₂ and R₃ and/or R₄ and R₅ together can form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents as defined herein, or R₂, R₃, R₄ and R₅ are
25 independently selected from an aromatic substituent as defined herein;

R₆ and R₇ are independently a substituent as defined herein or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A

and/or Formula B are covalently bonded together, e.g. via their respective R_1 substituents (Formula A) or via their R_6 or R_7 substituents (Formula B) or via a spacer group;


- 5 X^- is an anionic moiety, such as halogen (e.g. Cl^- , Br^- or I^-), tosylate or mesylate.

Examples of compounds represented by Formula B are set out below and include:

- 10 5-(2-tert-butylamino-ethyl)-phenanthridinium bromide;
5-(2-Piperidin-1-yl-ethyl)-phenanthridinium bromide;
piperazine phenanthridinium derivatives;
hydroxylamine derivatives;
1,5,9triazacyclododecane.

15

In a further aspect, the present invention provides a compound represented by Formula Bi:



- 20 wherein:

~~n is 2 to 5, more preferably 2-3, and most preferably 2;~~

R_1 is hydrogen or an aromatic substituent;

25

R_6 and R_7 are independently hydrogen, a substituent as defined herein or a linking group to form a multimeric compound in which a plurality of compounds represented by


Formula A and/or Formula B are covalently bonded together, e.g. via their respective R_1 substituents (Formula A) or via their R_6 or R_7 substituents (Formula B) or via a spacer group;

5

R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} and R_{16} are independently selected from hydrogen or an aromatic substituent as defined herein; and

10 X^- is an anionic moiety, such as halogen (e.g. Cl^- , Br^- or I^-), tosylate or mesylate.

In a further aspect, the present invention provides compounds represented by the Formula Bii:



15

wherein:

n is 2 to 5, more preferably 2-3, and most preferably 2;

20 R_1 is hydrogen or an aromatic substituent;

R_6 is hydrogen, a substituent as defined herein or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A and/or

25 Formula B are covalently bonded together, e.g. via their respective R_1 , R_6 and/or R_7 substituents;

R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅ and R₁₆ are independently selected from hydrogen or an aromatic substituent as defined herein; and

- 5 X⁻ is an anionic moiety, such as halogen (e.g. Cl⁻, Br⁻ or I⁻), tosylate or mesylate.

Examples of compounds represented by Formula Bii include the compound 5-[2-(4-methoxy-benzylsulfanyl)-ethyl]-
10 phenanthridinium bromide.

In all of the aspects of the invention, where the R₂ and R₃ and/or R₄ and R₅ substituents are present, it is preferred that one or both of these pairs of substituents
15 together form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents as defined herein.

In a further aspect, the present invention provides
20 a multimeric compound formed by covalently linking two or more of the compounds as defined above, which may be the same or different. The reaction to produce multimeric compounds according to the present invention may occur spontaneously when compounds of the invention are
25 synthesised or via an additional reaction. Conveniently, compounds of Formula A can be linked via the R₁ substituent and compounds represented by Formula B can be linked via the R₆ and/or R₇ substituents. Where the compounds are linked via the R₆ and R₇ substituents, the
30 resulting linkage can form a cycloalkyl group. By way of example, the compounds defined herein can be used to form dimers, trimer, tetramers or higher order multimers, e.g. by the use of one or more spacer groups. Examples of linker groups include C₁₋₇ alk-di-yl bonded to another

group of Formula A or B in place of R₁ thereof; piperazin-
di-yl bonded to another group of Formula A or B in place
of R₁ thereof; (N,N-C₁₋₆ dialkylene) C₁₋₇ alkylene amine
bonded to two other groups of Formula A or B in place of
5 R₁ thereof; or cyclo (C₄₋₈) alk-tri-yl bonded to two other
groups of Formula A or B in place of R₃ thereof.

In the present invention, spacer groups provide a skeleton
on which compounds of Formula A and/or B can be bonded.
10 Spacer groups can be used to form multimeric compounds
having 2 or more, 3 or more, 4 or more, 5 or more, 10 or
more, 20 or more, 50 or more, or 100 or more compounds
represented by Formula A or B linked via one or more
spacer groups. Examples of spacer groups are polyamine
15 compounds, examples of which are shown in Figure 2, which
comprise an alkyl chain having a plurality of functional
groups such as amines for reacting with the compounds of
Formula A and/or B as described herein. As well as the
compounds shown in Figure 2 in which compounds of the
20 present invention are grafted onto one spacer, it is
possible to envisage using a plurality of spacers bridged
by compounds of the present invention. This can allow the
synthesis of multimers having molecular weights of more
than about 10 kDa, more than about 20 kDa, more than about
25 30 kDa to a molecular weight range of about 30 to about 60
K Daltons, e.g. for a 100-mer.

Examples of multimeric compounds include:

30 Dimers:

Ethylene diamine derivative with two groups of Formula A.

Hydroxylamine derivative with two groups of Formula B.

Piperazine derivative with two groups of Formula B.

Trimers:

5

Tris (2-aminoethylamine) derivatives with three groups of Formula A

10

Cis-triaminocyclohexane derivatives with three groups of Formula A.

15

2-Amino-1-[5,9-bis-(2-amino-acetyl)-1,5,9triaza-cyclododec-1-yl]-ethanone derivative with three groups of Formula A.

20

2-[5,9-Bis-(2-amino-ethyl)-1,5,9triaza-cyclododec-1-yl]-ethylamine derivative with three groups of Formula A.

1,5,9-triaza-cyclododecane derivative with three groups of Formula B.

Tetramers:

25

Tetrakis-(6-amino-hexyl)-ammonium bromide derivative with four groups of Formula A.

30

In other aspects, the present invention provides methods for synthesising the compounds of the invention. The inventors have also elucidated the mechanism of these reactions which are unprecedented. The reaction to form compounds of Formula A proceeds via three coupled spontaneous reaction steps in a kind of cascade reaction. The sequence of the cascade is: alpha addition, cyclisation followed by an *in-situ* oxidation step. In one

embodiment of the invention (Method A), the *in-situ* oxidation step occurs via hydride loss and a second equivalent of the precursor that undergoes the initial alpha addition is also consumed as the hydride acceptor under the reaction conditions. This is the first observation of a reaction system that involves an alpha addition step (removing the aromatic nature of the ring) followed by cyclisation and spontaneous re-aromatisation of the ring via hydride loss. In a second embodiment of the method (Method B) for forming compounds represented by Formula A, the *in-situ* oxidation step uses an oxidizing agent, such as N-bromo-succinimide, to avoid the consumption of an equivalent of the phenanthridinium starting material. Alternatively, method B employs a biphasic solution of water/ethyl acetate and allows the isolation of the non-oxidized newly formed 5 or 6-membered ring in the organic layer whereas the excess of base and its HBr salt is eliminated by an aqueous wash. The non-oxidised intermediate in the ethyl acetate can then be oxidized by NBS to form the final molecule.

Advantageously, a buffer can be used (e.g. NaHCO_3 buffer) to avoid the pH of the reaction rising too much whereby a competitive reaction can take place in which hydroxide alpha addition leads to a pseudo-base adduct. Therefore preferably, the pH of the reaction is less than about 10, and more preferably is less than about 9. Further, it is preferred that an organic soluble base such as triethylamine is used. Without a base soluble in the organic solvent, one equivalent of intermediate can be lost by acting as a base on another intermediate forming the five membered ring cyclisation. The protonated intermediate would undertake a rapid ring opening leading to an alkyl chain substitution side product.

For primary amines, this second method B is much more advantageous than the first one. Nevertheless, the first Method A is generally preferred for the formation of dimers, trimers and multimers because, for solubility reasons, DMF is more appropriate. Method A is also better for the formation of [5-(2-amino-alkyl)-phenanthridiniums via the use of secondary amines.

10 Accordingly, the synthetic methods disclosed herein provide a strategy for the synthesis of the compounds of the invention. In the syntheses illustrated herein, the reaction of a primary amine is used to produce derivatives of [2,3-dihydro-1*H*-imidazo [1,2-*f*] phenanthridin-4-ylum bromide] or the reaction of a secondary amine is used to produce derivatives of [5-(2-amino-ethyl)-phenanthridinium. However, the reactions disclosed herein are general and can be extended to other heterocyclic aromatic moieties containing a ring nitrogen and at least one adjacent alpha hydrogen. Furthermore, the reactions are extremely easy to perform as isolating a pure final product simply requires a filtration and a washing procedure to afford product in high yield.

25 Accordingly, in a further aspect, the present invention provides a method of synthesising a heterocyclic aromatic cationic compound with an additional ring, the method comprising reacting a heterocyclic aromatic cationic compound comprising a ring nitrogen and at least one alpha hydrogen atom with a substituted or unsubstituted primary amine, a sulphate or a hydroxide, wherein the primary amine, sulphate or hydroxide reacts with the heterocyclic aromatic compound by alpha addition, cyclisation and an oxidation step thereby providing the heterocyclic aromatic


30

compound with an additional ring. In preferred
embodiments, the ring produced in this reaction is five
membered. In a preferred embodiment, the heterocyclic
aromatic compound, a primary amine is used to produce a
5 phenanthridinium compound such as 2-bromo-ethyl-
phenanthridinium bromide.

The method can be used for the production of 5 and 6-
membered rings and to produce thiazole and oxazoles as
10 well as phenanthridinium compounds by using a sulphate or
a hydroxide respectively. The Methods A and B described
herein are particularly advantageous as they involve an
addition and a cyclisation followed by an aromatisation
process that involves one equivalent of the starting
15 material as an oxidizing agent (Method A) or a external
oxidizing agent like NBS (Method B). In preferred
embodiments, this has the particular advantage that the
reaction can proceed in one pot. While the application of
this new chemistry to the production of phenanthridinium
20 compounds in which the **b** ring is extended is preferred,
the reaction is equally applicable to the extension of
other heteroaromatic compounds such as quinolines,
isoquinolines, quinazolines or pyridines.

25 In one embodiment, the method is for making a compound
represented by Formula A and comprises:


reacting a heterocyclic aromatic compound represented
by the Formula A':



wherein Y is a leaving group and n and the remaining substituents are as defined above;

with a primary amine represented by the formula:

5





wherein the R_a-C-R_b substituents of the primary amine forms the group R_1 in the final compound;

the primary amine reacting with the phenanthridinium compounds of Formula A' by addition, cyclisation and
10 oxidation to produce a compound represented by Formula A.


In further embodiments, the method of making a compound represented by Formula Ai or Aii, the method comprising:

reacting a heterocyclic aromatic compound represented
15 by the Formula Ai' or Aii' respectively:



wherein Y is a leaving group and the remaining
20 substituents are as defined above;

with a primary amine represented by the formula:



wherein the R_a-C-R_b substituents of the primary amine forms the group R_1 in the final compound;

the primary amine reacting with the phenanthridinium
5 compounds of Formula Ai' by addition, cyclisation and
oxidation to produce a compound represented by Formula Ai.

Examples of primary amines that can be reacted with
compounds of general Formula A include:

10

Aliphatic primary amines, which (1) have no substituents
in the alpha position (e.g. ammonia), (2) have a primary
carbon in the alpha position (e.g. methyl amine), (3) have
a secondary carbon in the alpha position (such as an alkyl
15 amine), (4) have a tertiary carbon in the alpha position
(such as isopropylamine or amino acids other than
glycine), or (5) are or derive from an amino acid.

Aromatic amines, and preferably aromatic amines without
20 bulky beta substituents such as naphthalen-1-ylamine or
anthracen-9-ylamine.

A hydrochloride of an aliphatic and aromatic amine are
described above.


25

The primary amines preferably do not include amines having
a quaternary carbon on its alpha position such as
isobutylamine or amines having a carbonyl in the alpha
position such as acetamide.

30


In a further aspect, the present invention provides a method of making compounds represented by Formula B, the method comprising:

5 reacting a heterocyclic aromatic compound represented by the Formula B':



wherein Y is a leaving group and the remaining substituents are as defined above;

with a secondary amine represented by the Formula:



10


the secondary amine reacting with the compound of Formula B' to produce a compound represented by Formula B.

15 Without wishing to be bound by a particular theory, the present inventors believe that the reaction to produce compounds represented by Formula B comprises nucleophilic attack of secondary amine on the compound of Formula B' to undergo alpha addition to the heteroaromatic ring, attack of the lone pair of the newly formed tertiary amine onto
20 the carbon linked to the leaving group Y, thereby causing this quaternary ammonium group to leave by attack of the lone pair on the heteroaromatic ring N to cause the alpha C-N bond to break and provide the product, with rearomatization being the driving force.

25


In a further aspect, the present invention provides a method of making compounds represented by Formula Bi, the method comprising:

reacting a heterocyclic aromatic compound represented by the Formula Bi':



wherein Y is a leaving group and the remaining
5 substituents are as defined above;


with a secondary amine represented by the formula:



the secondary amine reacting with the compound of
Formula Bi' by to produce a compound represented by
10 Formula Bi.

In a further aspect, the present invention provides a
method of making compounds represented by Formula Bii, the
method comprising:

15 reacting a heterocyclic aromatic compound represented
by the Formula Bii':



with a sulphur containing compound such as
substituted or unsubstituted thiol to produce a compound
20 represented by Formula Bii, e.g. as disclosed in the
examples below.

In the methods disclosed herein for the production of compounds of the present invention represented by Formula A or B, the method may comprise the additional step of
5 forming a multimeric compound.

Structure B is also formed through the one-pot three step mechanism. Some secondary amine substitutions on 2-bromo-ethyl-pyridinium salt derivatives other than 2-Bromo-ethyl-phenanthridinium have been described already in the
10 literature through an SN_2 mechanism. However, without wishing to be bound by any particular theory, the present inventors believe that this SN_2 mechanism is wrong and that the reaction proceeds via a non- SN_2 , non- SN_1
15 mechanism as described herein.

In a further aspect, the present invention provides a composition comprising one or more compounds as defined herein.
20

In a further aspect, the present invention provides a compound as defined herein for use in a method of medical treatment.

25 In a further aspect, the present invention provides the use of the compounds as defined herein as DNA cross linking agents, DNA binding agents, telomere binding agents, biological probes or diagnostic probes.

30 In a further aspect the present invention provides the use of the compounds defined herein for the preparation of a medicament for the treatment of a condition treatable by an anti-cancer agent, an anti-inflammatory agent, as antiprotozoal agent or a topoisomerase inhibitor.

In a further aspect, the present invention provides the use of a compound as defined herein as a synthetic agent, by way of example, as a reducing agent, a chiral reducing reagent (that is a substance that is capable of reducing an achiral substrate to selectively produce more of a given enantiomer over another), an amine protecting group, a phase transfer catalyst, a chiral resolving agent for purification or crystallisation.

10

In a further aspect, the present invention provides the use of a compound as defined herein as an electronic material, a photochemically active agent or sensor or as molecular switching device.

15

Other areas of use of the compounds include the use of these new frameworks in combinatorial chemistry to form biologically active components that are active in areas other than DNA binding and these may be, for instance, dopamine inhibitors, NADH mimics and as a general heterocyclic fragment for drug design to cover the area of alkaloid chemistry.

Other preferred areas of application of the compounds include their use as DNA binders as anti cancer drugs and other drugs that need to target DNA, ageing moderators, DNA binding tools for molecular biology, gene expression, DNA sensors and spectroscopically active DNA binding and bending sensors, new heterocyclic frameworks for drug discovery, dopamine drugs, NADH-based drugs, spectroscopically active binding molecules.

30

To elaborate on the use of the aforementioned compounds as genomic probes and diagnostic agents, given the ease of

the reaction, and the number of DNA intercalating units that can be linked together using this technology, it is possible to produce libraries of tethered units that can be used to detect a given gene etc, see Figure 2.

5

In this way, an infinitely variable library of DIP-based molecules can be produced and supported on a gold surface to perform Surface Plasmon Resonance studies (SPR).

Therefore, DIP-based (formula A) or extended heterocyclic cations (formula B) molecules can be used as biosensor to identify binding events with DNA flowing across the surface. This or a related technology can be used to provide specific gene targeting using a molecular library generated using the molecules of the type A or B.

15

Embodiments of the invention will now be described in more detail, by way of example and not limitation, with reference to the accompanying figures.

20 Brief Description of the Figures

Figure 1 shows a schematic diagram indicating how the compounds of the present invention, including dimers, trimer and tetramers are constructed and how they might intercalate with DNA.

25

Figure 2 shows a schematic diagram showing how multimeric compounds can be formed from compounds of the present invention using spacer groups.

30 Figure 3 shows a plot of IC50 values when compounds according to the present invention and cisplatin and carboplatin are contacted with three different tumour cell lines (A2780, A2780/cp70 and MCP1).

Detailed Description

Abbreviations

For convenience, many chemical moieties are represented
5 using well known abbreviations, including but not limited
to, methyl (Me), ethyl (Et), n-propyl (nPr), iso-propyl
(iPr), n-butyl (nBu), sec-butyl (sBu), iso-butyl (iBu),
tert-butyl (tBu), n-hexyl (nHex), cyclohexyl (cHex),
phenyl (Ph), biphenyl (biPh), benzyl (Bn), naphthyl
10 (naph), methoxy (MeO), ethoxy (EtO), benzoyl (Bz), and
acetyl (Ac), and triethylamine (TEA).

For convenience, many chemical compounds are represented
using well known abbreviations, including but not limited
15 to, methanol (MeOH), ethanol (EtOH), iso-propanol (i-
PrOH), methyl ethyl ketone (MEK), ether or diethyl ether
(Et₂O), acetic acid (AcOH), dichloromethane (methylene
chloride, DCM), acetonitrile (ACN), trifluoroacetic acid
(TFA), dimethylformamide (DMF), tetrahydrofuran (THF), and
20 dimethylsulfoxide (DMSO).

General Substituents

As indicated herein, the compounds of the present
invention may be unsubstituted or substituted by one or
25 more functional groups. Unless otherwise specified, the
term "substituted" means a parent group which bears one or
more substituents. The term "substituent" is used herein
in the conventional sense and refers to a chemical moiety
which is covalently attached to, appended to, or if
30 appropriate, fused to, a parent group. A wide variety of
substituents are well known in the art, and methods for
their formation and introduction into a variety of parent
groups are also well known.

In the present invention, "aromatic substituent" as defined herein are independently selected from hydrogen, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -SH, -SMe, -SEt, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -CONH₂, -CONHMe, -NH₂, -NMe₂, -NEt₂, -N(nPr)₂, -N(iPr)₂, -CN, -NO₂, -Me, -Et, -CF₃, -OCF₃, -CH₂OH, -CH₂CH₂OH, -CH₂NH₂, -CH₂CH₂NH₂, -Ph, ether (e.g., C₁₋₇alkoxy); ester; amido; amino; and, C₁₋₇alkyl (including, e.g., unsubstituted C₁₋₇alkyl, C₁₋₇haloalkyl, C₁₋₇hydroxyalkyl, C₁₋₇carboxyalkyl, C₁₋₇aminoalkyl, C₅₋₂₀aryl-C₁₋₇alkyl).

In the present invention, "substituent" as defined herein are independently selected from hydrogen, halo; hydroxy; oxo; ether (e.g., C₁₋₇alkoxy); formyl; acyl (e.g., C₁₋₇alkylacyl, C₅₋₂₀arylacyl); acylhalide; carboxy; ester; acyloxy; amido; acylamido; thioamido; tetrazolyl; amino; nitro; nitroso; azido; cyano; isocyano; cyanato; isocyanato; thiocyano; isothiocyano; sulfhydryl; thioether (e.g., C₁₋₇alkylthio); sulfonic acid; sulfonate; sulfone; sulfonyloxy; sulfinyloxy; sulfamino; sulfonamino; sulfinamino; sulfamyl; sulfonamido; C₁₋₇alkyl (including, e.g., unsubstituted C₁₋₇alkyl, C₁₋₇haloalkyl, C₁₋₇hydroxyalkyl, C₁₋₇carboxyalkyl, C₁₋₇aminoalkyl, C₅₋₂₀aryl-C₁₋₇alkyl); C₃₋₂₀heterocyclyl; or C₅₋₂₀aryl (including, e.g., C₅₋₂₀carboaryl, C₅₋₂₀heteroaryl, C₁₋₇alkyl-C₅₋₂₀aryl and C₅₋₂₀haloaryl)).

In one preferred embodiment, the substituent(s) are independently selected from:

-F, -Cl, -Br and -I;
=O
-OH;
-OMe, -OEt, -O(tBu) and -OCH₂Ph;
-SH;

- SMe, -SEt, -S(tBu) and -SCH₂Ph;
- C(=O)H;
- C(=O)Me, -C(=O)Et, -C(=O)(tBu) and -C(=O)Ph;
- C(=O)OH;
- 5 -C(=O)OMe, -C(=O)OEt and -C(=O)O(tBu);
- C(=O)NH₂, -C(=O)NHMe, -C(=O)NMe₂ and -C(=O)NH₂Et;
- NHC(=O)Me, -NHC(=O)Et, -NHC(=O)Ph, succinimidyl and maleimidyl;
- NH₂, -NHMe, -NH₂Et, -NH(iPr), -NH(nPr), -NMe₂, -NEt₂,
- 10 -N(iPr)₂, -N(nPr)₂, -N(nBu)₂ and -N(tBu)₂;
- CN;
- NO₂;
- Me, -Et, -nPr, -iPr, -nBu and -tBu;
- CF₃, -CHF₂, -CH₂F, -CCl₃, -CBr₃, -CH₂CH₂F, -CH₂CHF₂ and
- 15 -CH₂CF₃;
- OCF₃, -OCHF₂, -OCH₂F, -OCCl₃, -OCBr₃, -OCH₂CH₂F, -OCH₂CHF₂ and -OCH₂CF₃;
- CH₂OH, -CH₂CH₂OH and -CH(OH)CH₂OH;
- CH₂NH₂, -CH₂CH₂NH₂ and -CH₂CH₂NMe₂; and,
- 20 substituted or unsubstituted phenyl.

For phenyl substituents, if the phenyl group has less than the full complement of substituents, they may be arranged in any combination. For example, if the phenyl group has

25 a single substituent other than hydrogen, it may be in the 2-, 3-, or 4-position. Similarly, if the phenyl group has two substituents other than hydrogen, they may be in the 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-positions. If the phenyl group has three substituents other than hydrogen,

30 they may be in, for example, the 2,3,4-, 2,3,5-, 2,3,6-, 2,4,5-, 2,5,6-, or 3,4,5-positions. If the phenyl group has four substituents other than hydrogen, they may be in, for example, the 3,4,5,6-, 2,4,5,6-, 2,3,5,6-, 2,3,4,6-, or 2,3,4,5-positions.

In one preferred embodiment, the substituent(s), often referred to herein as R_1 to R_{17} , are independently selected from:

- 5 -OH;
 =O
 -OMe, -OEt, -O(tBu) and -OCH₂Ph;
 -C(=O)OMe, -C(=O)OEt and -C(=O)O(tBu);
 -C(=O)NH₂, -C(=O)NHMe, -C(=O)NMe₂ and -C(=O)NH₂Et;
10 -NH₂, -NHMe, -NH₂Et, -NH(iPr), -NH(nPr), -NMe₂, -NEt₂,
 -N(iPr)₂, -N(nPr)₂, -N(nBu)₂ and -N(tBu)₂;
 -Me, -Et, -nPr, -iPr, -nBu, -tBu;
 -CF₃, -CHF₂, -CH₂F, -CCl₃, -CBr₃, -CH₂CH₂F, -CH₂CHF₂, and
 -CH₂CF₃;
15 -CH₂OH, -CH₂CH₂OH, and -CH(OH)CH₂OH; and,
 -CH₂NH₂, -CH₂CH₂NH₂ and -CH₂CH₂NMe₂.

Alternative Forms of Compounds

- The compounds of the invention may be derivatised in various ways. As used herein "derivatives" of the compounds includes well known ionic, salt, solvate and protected forms of the compounds or their substituents mentioned herein. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form
20 (-COO⁻), a salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-N⁺HR¹R²), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected
25 forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-O⁻), a salt or solvate thereof, as well as conventional protected forms.
- 30


Isomers, Salts, Solvates, Protected Forms, and Prodrugs

Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α and β -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").

Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers", as used herein, are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, $-\text{OCH}_3$, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, $-\text{CH}_2\text{OH}$. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C_{1-7} alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol

(illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.



- 5 Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ^1H , ^2H (D), and ^3H (T); C may be in any isotopic form, including ^{12}C , ^{13}C , and ^{14}C ; O may be in any isotopic form, including ^{16}O and ^{18}O ; and the like.

- Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof.
- 15 Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known
- 20 manner.

- It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples
- 25 of pharmaceutically acceptable salts are discussed in Berge et al, Pharmaceutically Acceptable Salts, J. Pharm. Sci., Vol. 66: 1-19, 1977.

- For example, if the compound is anionic, or has a
- 30 functional group which may be anionic (e.g., $-\text{COOH}$ may be $-\text{COO}^-$), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are

not limited to, alkali metal ions such as Na^+ and K^+ , alkaline earth cations such as Ca^{2+} and Mg^{2+} , and other cations such as Al^{3+} . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH_4^+) and substituted ammonium ions (e.g., NH_3R^+ , NH_2R_2^+ , NHR_3^+ , NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $\text{N}(\text{CH}_3)_4^+$.

If the compound is cationic, or has a functional group which may be cationic (e.g., $-\text{NH}_2$ may be $-\text{NH}_3^+$), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable

polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.

5 It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g., active compound, salt of active compound) and solvent. If
10 the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.

It may be convenient or desirable to prepare, purify,
15 and/or handle the active compound in a chemically protected form. The term "chemically protected form" is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical
20 reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like). In practice, well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions.
25 In a chemically protected form, one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a reactive functional group, reactions involving other unprotected
30 reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, Protective Groups in Organic Synthesis

(T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999).

A wide variety of such "protecting", "blocking" or
5 "masking" methods are widely used and well known in
organic synthesis. For example, a compound which has two
nonequivalent reactive functional groups, both of which
would be reactive under specified conditions, may be
derivatized to render one of the functional groups
10 "protected" and therefore unreactive, under the specified
conditions; so protected, the compound may be used as a
reactant which has effectively only one reactive
functional group. After the desired reaction (involving
the other functional group) is complete, the protected
15 group may be "deprotected" to return it to its original
functionality.

For example, a hydroxy group may be protected as an ether
(-OR) or an ester (-OC(=O)R), for example, as: a t-butyl
20 ether; a benzyl, benzhydryl (diphenylmethyl), or trityl
(triphenylmethyl) ether; a trimethylsilyl or
t-butyldimethylsilyl ether; or an acetyl ester (-
OC(=O)CH₃, -OAc).

25 For example, an aldehyde or ketone group may be protected
as an acetal (R-CH(OR)₂) or ketal (R₂C(OR)₂), respectively,
in which the carbonyl group (>C=O) is converted to a
diether (>C(OR)₂), by reaction with, for example, a
primary alcohol. The aldehyde or ketone group is readily
30 regenerated by hydrolysis using a large excess of water in
the presence of acid.

For example, an amine group may be protected, for example,
as an amide (-NRCO-R) or a urethane (-NRCO-OR), for

example, as: a methyl amide ($-\text{NHCO}-\text{CH}_3$); a benzyloxy amide ($-\text{NHCO}-\text{OCH}_2\text{C}_6\text{H}_5$, $-\text{NH}-\text{Cbz}$); as a t-butoxy amide ($-\text{NHCO}-\text{OC}(\text{CH}_3)_3$, $-\text{NH}-\text{Boc}$); a 2-biphenyl-2-propoxy amide ($-\text{NHCO}-\text{OC}(\text{CH}_3)_2\text{C}_6\text{H}_4\text{C}_6\text{H}_5$, $-\text{NH}-\text{Bpoc}$), as a 9-fluorenylmethoxy amide ($-\text{NH}-\text{Fmoc}$), as a 6-nitroveratryloxy amide ($-\text{NH}-\text{Nvoc}$), as a 2-trimethylsilylethyloxy amide ($-\text{NH}-\text{Teoc}$), as a 2,2,2-trichloroethyloxy amide ($-\text{NH}-\text{Troc}$), as an allyloxy amide ($-\text{NH}-\text{Alloc}$), as a 2(-phenylsulphonyl)ethyloxy amide ($-\text{NH}-\text{Psec}$); or, in suitable cases (e.g., cyclic amines),
10 as a nitroxide radical ($>\text{N}-\text{O}$).

For example, a carboxylic acid group may be protected as an ester for example, as: an C_{1-7} alkyl ester (e.g., a methyl ester; a t-butyl ester); a C_{1-7} haloalkyl ester
15 (e.g., a C_{1-7} trihaloalkyl ester); a tri C_{1-7} alkylsilyl- C_{1-7} alkyl ester; or a C_{5-20} aryl- C_{1-7} alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.

20 For example, a thiol group may be protected as a thioether ($-\text{SR}$), for example, as: a benzyl thioether; an acetamidomethyl ether ($-\text{S}-\text{CH}_2\text{NHC}(=\text{O})\text{CH}_3$).

It may be convenient or desirable to prepare, purify,
25 and/or handle the active compound in the form of a prodrug. The term "prodrug" as used herein, means a compound which, when metabolised (e.g., in vivo), yields the desired active compound. Typically, the prodrug is inactive, or less active than the active compound, but may
30 provide advantageous handling, administration, or metabolic properties.

For example, some prodrugs are esters of the active compound (e.g., a physiologically acceptable metabolically

labile ester). During metabolism, the ester group ($-C(=O)OR$) is cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups ($-C(=O)OH$) in the parent
5 compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.

Examples of such metabolically labile esters include those
10 of the formula $-C(=O)OR$ wherein R is: C_{1-7} alkyl (e.g., $-Me$, $-Et$, $-nPr$, $-iPr$, $-nBu$, $-sBu$, $-iBu$, $-tBu$); C_{1-7} aminoalkyl (e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2-(4-morpholino)ethyl); and acyloxy- C_{1-7} alkyl (e.g., acyloxymethyl; acyloxyethyl;
15 pivaloyloxymethyl; acetoxymethyl; 1-acetoxyethyl; 1-(1-methoxy-1-methyl)ethyl-carboxyloxyethyl; 1-(benzoyloxy)ethyl; isopropoxy-carboxyloxymethyl; 1-isopropoxy-carboxyloxyethyl; cyclohexyl-carboxyloxymethyl; 1-cyclohexyl-carboxyloxyethyl;
20 cyclohexyloxy-carboxyloxymethyl; 1-cyclohexyloxy-carboxyloxyethyl; (4-tetrahydropyranyloxy)carboxyloxymethyl; 1-(4-tetrahydropyranyloxy)carboxyloxyethyl; (4-tetrahydropyranyl)carboxyloxymethyl; and
25 1-(4-tetrahydropyranyl)carboxyloxyethyl).

Also, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for
30 example, as in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.

Solvents

Solvents may conveniently be classified according to one or more of their physical or chemical properties. For example, solvents may be classified according to their polarity, that is, their permanent dipole moment.

Examples of highly polar solvents include dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, and acetonitrile (ACN). Examples of moderately polar solvents include acetone, methanol, tetrahydrofuran (THF), ethyl acetate (AcOEt), and water. Examples of relatively non-polar solvents include diethyl ether, chloroform, and dichloromethane (DCM). Examples of non-polar and virtually non-polar solvents include alkanes, benzene, toluene, and carbon tetrachloride.

Solvents may also be classified as "protic" or "aprotic" according to their proton-exchange properties. Protic solvents accept and/or donate protons. Examples of protic solvents include water, alcohols, carboxylic acids (e.g., acetic acid), and amines (e.g., ammonia, pyridine). Aprotic solvents neither accept nor donate protons. Examples of aprotic solvents include carbon tetrachloride, chloroform, dichloromethane (DCM), acetonitrile (ACN), ethyl acetate (AcOEt), dimethylacetamide, tetrahydrofuran (THF), dimethylformamide (DMF), toluene, benzene, acetone, ethers (e.g., diethyl ether), alkanes (e.g., hexane), dimethylsulfoxide (DMSO), sulfur dioxide, hexamethylphosphoramide (HMPA), and, tetramethylurea.

Amphoteric solvents, such as water, are capable of both accepting and donating protons.

Solvents may also be classified as "organic" or "inorganic" according to their chemical composition. Conventionally, organic solvents comprise, at least,

carbon atoms, while inorganic solvents do not. Examples of inorganic solvents include water, ammonia, and sulfur dioxide. Examples of organic solvent include carbon tetrachloride (CCl_4); chloroform (CHCl_3); dichloromethane (DMC, CH_2Cl_2); acetonitrile (ACN); ethyl acetate (AcOEt); ethanol (EtOH); methanol (MeOH); dimethylacetamide; tetrahydrofuran (THF); dimethylformamide (DMF); toluene; benzene; acetone; ethers (e.g., diethyl ether); alkanes (e.g., hexane); water; liquid ammonia; dimethylsulfoxide (DMSO); sulfur dioxide, hexamethylphosphoramide (HMPA); tetramethylurea; tetramethylene sulfone (sulfolane).

Applications of the Compounds

The compounds of the present invention can be used in the field of biology as a DNA cross linking agent, a DNA binding agent, a telomere binding agent, a drug such as an anti-cancer drug, a diagnostic probe, a probe for molecular biology, an anti-inflammatory agent, an antiprotozoal agent, a topoisomerase inhibitor and/or a bioactive drug or cofactor.

The compounds of the present invention can be used as synthetic agents, by way of example, as reducing agents, chiral reagents, chiral reducing agents, amine protecting groups or phase transfer catalysts.

The compounds of the present invention can be used as in the production of electronic materials, photochemically active agents and sensors, or as molecular switching devices.

DNA binding

The concepts behind the design of these molecules for DNA binding is given in Figure 1. DNA intercalation occurs by

insertion of a flat aromatic system in between two sets of DNA base pairs, see for example the paper 'Intercalators as Anticancer Drugs' by M. F. Brana et al in Current Pharmaceutical Design, 2001, 7, 1745.

5

Biology

Generally, the compounds of the present invention are water soluble molecules, but are sufficiently lipophilic to be capable of crossing the plasmic membrane and nuclear
10 membrane of the cells. They also preferably have high affinities for DNA. These properties mean that the compounds may find use in pharmaceuticals. To investigate this, examples of compounds of the present invention have been tested in cell cytotoxicity assays, comparing their
15 properties to cisplatin and carboplatin, two known cross-linking agents used in the treatment of cancer.

Compounds were tested in a growth assay with a 24 hours drug exposure and a 3 day recovery period. Cell lines
20 used were human ovarian tumour cell line A2780 and 2 Cisplatin resistant derivatives cell lines A27080/cp70 and MCP1. IC_{50} is the concentration of drug required to reduce the surviving cell number to 50% of that of the control untreated cells. Results are from one experiment
25 and are the mean \pm SEM of the triplicate plates.

The compounds of the invention were found to be cytotoxic to non-resistant and resistant cisplatin cell lines with IC_{50} 's between those of cisplatin and carboplatin. While
30 not wishing to be bound by any particular theory, the present inventors believe that the high affinity of the compounds for DNA means that the cytotoxic effect of the compounds is more DNA targeted than cisplatin or carboplatin which do not have any intrinsic DNA affinity.

Preferred compounds of the invention are stable molecules and are resistant to NADH reduction, unlike some other phenanthridinium derivatives which are not. This may help
5 to increase the bio-availability of the drug since some typical phenanthridinium derivatives have the drawback of being metabolised quickly by reduction reaction in the liver involving NADH. The compounds of the present invention also tend to be more alkali resistant than other
10 phenanthridinium derivatives which have the disadvantage of undertaking easily alpha addition of a hydroxide at physiological pH forming non-planar pseudo-base. The DIP framework is stable up to pH 11 where less than half of the molecules undertake the alpha addition of a hydroxide.
15 With typical phenanthridinium derivatives bearing one hydrogen on their alpha position, more than half of the molecules undertake a pseudo-base formation at pH above 8.5. By way of illustration, this is based on spectroscopic measurement where $pK_a(OH)$ of DIP frameworks
20 were found above 11, whereas $pK_a(OH)$ of the reference 5-methyl-phenanthridinium bromide were found below 8.5. The DIP framework has therefore the advantage of keeping its planarity at physiological pH to interact with DNA. The other phenanthridinium derivatives undertake to some
25 extend the pseudo-base formation at physiological pH, disturbing the planarity of the molecule and therefore losing part of their affinity for the DNA.

The compounds of the present invention are generally
30 highly stable to base and acid. This means that the compounds could be suitable for oral administration.

Without wishing to be bound by any particular theory, the present inventors believe that the compounds of the

invention can be modified and tuned so that they could be, for instance, subject to reduction or pseudo-base formation upon DNA intercalation. The stability of the DIP framework could be controlled by finding the right
5 substituent so that the molecule could be switched in the DNA duplex to an inactive form (this is not limited to but may include reduction or pseudo base formation). This means that the drug will be particularly effective in cells that are undergoing fast turnover i.e. cancer cells
10 but in slow growing cells, like most normal cells, the drug will be much less toxic. Thus, the DIP framework has the possibility to be tuned to be more toxic in fast growing cells like cancer cells, because the cells would not have enough time to undertake the metabolisation
15 process.








Finally, the DIP framework has a positive charge which is easily delocalized between its two nitrogen atoms. The molecule could therefore adjust the position of its charge
20 to increase the DNA binding, notably the ionic interaction between its cationic ammonium and the anionic phosphate backbone of the DNA duplex.





In summary, the compounds of the present invention may
25 have a range of properties that make them suitable for use as pharmaceuticals.

1. The compounds are typically amphiphilic, with their lipophilic nature being useful for crossing cell
30 membranes, whereas their hydrophilic character is important for the solubilisation of the drug in the blood stream.

2. Experiments also indicate that the compounds possess a high DNA affinity in DNA melting point experiments.
3. The cytotoxicity of the first lead compounds already
5 between Cisplatin and Carboplatin, as shown in the experiments reported herein, and are equally cytotoxic on non-resistant and resistant Cisplatin cell lines.
4. The DNA affinity properties of the compounds of the
10 present invention may mean that their cytotoxicity is more DNA targeted than Cisplatin or Carboplatin which do not have any intrinsic DNA affinity.
5. The DIP framework is more NADH stable than typical
15 phenanthridinium derivative. This could lead to a better bioavailability.
6. Compounds based on the DIP framework should be
suitable for oral administration.
- 20 7. The DIP framework could offer some drug targeting advantages by tuning the stability of the molecule so that normal cells would have enough time to undertake the destructive metabolism process, whereas the cancerous
25 fast growing cells would not.
8. The DIP framework could position its positive charge on one or the other of its nitrogen atoms through conjugation in order to increase the ionic interaction
30 with the DNA.

Cytotoxicity results

Compound	IC ₅₀		
	A2780	A2780/cp70	MCP1
 Cisplatin	0.091 ± 0.01	0.842 ± 0.136	0.185 ± 0.031
 Carboplatin	5.22 ± 0.14	41.1 ± 10.1	7.31 ± 0.56
 Ethidium Bromide	0.3 ± 0.039	0.658 ± 0.118	0.451 ± 0.008
 AP4-27	16.43 ± 3.37	13.23 ± 0.83	21.74 ± 0.92
 AP4-71	3.73 ± 0.23	4.28 ± 0.49	2.21 ± 0.92
 AP3-42	8.02 ± 1.14	7.29 ± 0.38	9.44 ± 0.58
 AP4-55	2.21 ± 0.22	1.35 ± 0.31	1.16 ± 0.19

 AP3-80	5.07 ± 1.06	4.54 ± 0.70	5.68 ± 0.86
 AP3-56	1.32 ± 0.09	1.82 ± 0.19	1.44 ± 0.16
 AP4-20	9.77 ± 1.04	16.51 ± 0.80	6.30 ± 0.09
 AP4-48	18.44 ± 1.23	16.77 ± 0.54	11.68 ± 1.51

Medical Uses and Pharmaceutical Compositions

In view of the above results, the compounds of the present invention may be formulated as pharmaceutical and used
5 method of medical treatment, in particular for the treatment of cancer, inflammation, protozoa or to inhibit a topoisomerase.

The properties of the compounds of the invention referred
10 to herein specifically includes both compounds with intrinsic activity (drugs) as well as prodrugs of such compounds, which prodrugs may themselves exhibit little or no intrinsic activity.

15 The compounds described herein or their derivatives can be formulated in pharmaceutical compositions, and

administered to patients in a variety of forms, in particular to treat conditions which are ameliorated by the administration of a compound according to the present invention. Pharmaceutical compositions for oral
5 administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant or an inert diluent. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable
10 oils, mineral oil or synthetic oil. Physiological saline solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. Such compositions and preparations generally contain at least 0.1wt% of the compound.

15 Parental administration includes administration by the following routes: intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraocular, transepithelial, intraperitoneal and topical (including dermal, ocular,
20 rectal, nasal, inhalation and aerosol), and rectal systemic routes. For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
25 Those of relevant skill in the art are well able to prepare suitable solutions using, for example, solutions of the compounds or a derivative thereof, e.g. in physiological saline, a dispersion prepared with glycerol,
30 liquid polyethylene glycol or oils.

In addition to one or more of the compounds, optionally in combination with other active ingredient, the compositions can comprise one or more pharmaceutically acceptable

ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.

Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts such as Handbook of Pharmaceutical Additives, 2nd Edition (eds. M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA), Remington's Pharmaceutical Sciences, 19th edition, Mack Publishing Company, Easton, Pa., 1995; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

In a further aspect, the present invention provides a method of making a pharmaceutical composition comprising admixing at least one compound as defined herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the active compound.

The term "pharmaceutically acceptable" as used herein pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, diluent, excipient, etc. must also be "acceptable" in the

sense of being compatible with the other ingredients of the formulation.

5 The formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the
10 active compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.

15 The formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.

The pharmaceutically compositions may be given to an individual in a "prophylactically effective amount" or a
20 "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. Typically, this will be to cause a therapeutically useful activity providing benefit to the individual. The actual
25 amount of the compounds administered, and rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical
30 doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in

Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 19th edition, 1995.

It will be appreciated by one of skill in the art that
5 appropriate dosages of the active compounds, and
compositions comprising the active compounds, can vary
from patient to patient. Determining the optimal dosage
will generally involve the balancing of the level of
10 therapeutic benefit against any risk or deleterious side
effects. The selected dosage level will depend on a
variety of factors including, but not limited to, the
activity of the particular compound, the route of
administration, the time of administration, the rate of
excretion of the compound, the duration of the treatment,
15 other drugs, compounds, and/or materials used in
combination, the severity of the condition, and the
species, sex, age, weight, condition, general health, and
prior medical history of the patient. The amount of
compound and route of administration will ultimately be at
20 the discretion of the physician, veterinarian, or
clinician, although generally the dosage will be selected
to achieve local concentrations at the site of action
which achieve the desired effect without causing
substantial harmful or deleterious side-effects.

25

Administration can be effected in one dose, continuously
or intermittently (e.g., in divided doses at appropriate
intervals) throughout the course of treatment. Methods of
determining the most effective means and dosage of
30 administration are well known to those of skill in the art
and will vary with the formulation used for therapy, the
purpose of the therapy, the target cell(s) being treated,
and the subject being treated. Single or multiple
administrations can be carried out with the dose level and

pattern being selected by the treating physician, veterinarian, or clinician.

5 In general, a suitable dose of the active compound is in the range of about 100 μ g to about 250 mg per kilogram body weight of the subject per day, and more typically in dosages of between about 1.0 and 100 mg per kilogram of body weight of the subject per day.

10 Further, the compositions of the invention may further comprise one or more other pharmaceutically active agents, either further compounds of the invention, or other drugs.

Experimental

15 Primary Amines

Introduction


In one aspect, the present invention relates to a new class of heterocyclic aromatic cation that is easily prepared in a 'one-pot' reaction system between a
20 phenanthridinium precursor and almost any primary amine with yields that are typically between 61 and 98 %, without the need for further purification. Such heterocyclic aromatic cations are currently of great interest due to their high affinity for DNA via
25 intercalation and their application as dyes, probes, and anti-tumour drugs.

The reaction pathway that yields these new heterocyclic aromatic cations has been elucidated and is unprecedented.
30 It was established that the reaction proceeds via three coupled spontaneous reaction steps in a kind of cascade reaction. The sequence of the cascade is: alpha addition, cyclisation followed by an *in-situ* oxidation step.

The *in-situ* oxidation step occurs via hydride loss and a second equivalent of the precursor that undergoes the initial alpha addition is also consumed as the hydride acceptor under the reaction conditions. This is the first
 5 observation of a reaction system that involves an alpha addition step (removing the aromatic nature of the ring) followed by cyclisation and spontaneous re-aromatisation of the ring via hydride loss.

10 The intermediates of the cascade reaction have been characterised in solution using a novel NMR-phase transfer procedure. This provides strong support for the assignment of the proposed reaction pathway.

15 A route to the systematic variation of desired properties is given by the ability to form the target molecules with almost any type of primary amine; furthermore, the same process can occur with the quinolinium derivative. The wider applicability of this reaction means that it will
 20 find great utility in organic synthesis.




The present invention relates to a new class of
 25 heterocyclic aromatic cation which has been isolated from the reaction of a 2-bromo-ethyl-phenanthridinium bromide with several types of primary amine in excellent yields. The reaction pathway has been found to proceed via an alpha addition step followed by cyclisation to form a

five-membered ring as an imidazolidine-based intermediate. The imidazolidine intermediate then undergoes hydride loss, yielding a rearomatized dihydro-1*H*-imidazo [1,2-*f*] phenanthridinium moiety; this process occurs by hydride transfer to a second equivalent 2-bromo-ethyl-phenanthridinium bromide. Furthermore, this cascade reaction appears to be general for all types of primary amine and has also been extended by replacing the phenanthridinium moiety by a quinolinium derivative.

Surprisingly, despite their wide application, previous work exploring ring extensions of the phenanthridinium core has been limited to the aromatic cycles **a** and **c** leaving the heteroaromatic middle ring **b**, unexplored.









Herein, an unprecedented reaction system is presented that allows the isolation of a new class of heteroaromatic framework through a ring-extension process. This ring extension involves the central ring **b** of the phenanthridinium core in the formation of a five-membered ring, comprising a dihydro-imidazo moiety. This moiety is derived from the phenanthridinium core whereby primary amine **1** reacts (in DMF) with 2-bromo-ethyl-phenanthridinium bromide **2** to give 2,3-dihydro-1*H*-imidazo [1,2-*f*] phenanthridinium, molecule **6** (**Scheme 1**). The formation of **6** can be explained by two distinctive pathways; **pathway A** involves the following processes: alpha addition, cyclisation and *in situ* oxidation reaction via a hydride loss, whereas **pathway B** involves nucleophilic substitution at the ethyl-bromide side chain before cyclisation and hydride loss.



Scheme 1. The two hypothetical reaction pathways, along with intermediates, to the new heteroaromatic cation framework **6(a-j)**.

5

The nature of this reaction seems not to depend on the amine employed because, by using one general synthetic procedure, a large variety of amines were found to undergo the same transformation in excellent yields, including aromatic amines (**Table 1**). The synthetic procedure itself is extremely simple (see experimental section) and the products **6(a-k)** isolated by precipitation are found to be analytically pure (see supplementary details for full analytical data).

Entry	Structure	Primary amine 1	Yield (%)
6a		4-Methoxybenzylamine	95
6b		Ethanolamine	98
6c		Ammonia	61
6d		Isopropylamine	82
6e		Cyclopropylamine	78
6f		L-alanine methoxycarbonyl	63
6g		Ethylenediamine	98
6h		tris(2-Aminoethyl)amine	95




6i		<i>cis</i> -1,3,5-Triaminocyclohexane	91
6j		4-Methoxyaniline	74
6k		Aniline	73


Table 1. Results from preliminary studies showing that the reaction is general for all types of primary amine.

5 Strong evidence in favor of pathway A has been found. Firstly, intermediate 4d was isolated via a phase transfer reaction in an NMR tube whereby the reaction is initiated in a biphasic solvent system containing D₂O and CDCl₃ (1:1). In this way, the first step of the reaction takes
10 place in the D₂O layer, but the second step proceeds in the organic layer as 3, insoluble in D₂O, immediately shifts toward the chlorinated phase once it is formed. Cyclisation occurs spontaneously, yielding molecule 4, which is soluble in organic solvents and therefore,
15 reaction with molecule 2 is prevented. The redox step, which involves hydride transfer from molecule 4 to molecule 2, cannot occur and this allows 4d to be unambiguously identified (see supplementary data for details).

20

However, the postulated second intermediate 4 is common to both pathways (Scheme 1), and isolation of intermediate 3

and/or 3' is required to aid mechanistic analysis. To investigate this, experiments were devised and conducted to examine the intermolecular reactivity between the amine and the aromatic alpha position of the fluoro- and hydroxy- analogues of molecule 2, (7a and 7b, respectively. Scheme 2). In conducting these experiments, we assumed that the electrophilic nature and hence reactivity of the alpha position in analogues 7a and 7b is similar to that of molecule 2. However, these analogues are unable to cyclise and therefore the reaction does not proceed past the alpha addition step, but provide us with circumstantial evidence regarding the reactivity of the alpha position in molecule 2.



Scheme 2. NMR phase transfer experiment with the fluoro (7a) and hydroxy (7b) analogues of molecule 2. a: X = F; b: X = OH

These experiments were also performed using a NMR phase transfer experiment and 8a,b and 9a,b were characterized (in the CDCl_3 layer) by ^1H and ^{13}C NMR. These results reveal that the alpha addition step can occur via an intermolecular reaction process, and proceeds to


completion within one minute. Indeed, no starting material was found in the aqueous layer after this time.

Eventually, intermediate 3 was obtained by designing an experiment that utilized a hindered primary amine (Scheme 3). In this case, a NMR phase transfer reaction was conducted with (R)-(+)-1-(4-methoxyphenyl)ethylamine as both nucleophile and base. As expected, the first alpha addition step is observed and compound 3k is formed.

10 However, to form 4k, the proton of the quaternary amine of the cationic form of 3k has to be removed by the base. In this case, it appears that a second molecule of 4-methoxyphenylethylamine is too hindered to approach the sterically crowded complex 3k to act as a base. Equally,

15 it was observed that TEA is not able to trigger the cyclisation process. However, if ammonium chloride is added to the TEA solution, free ammonia is produced which appears to be small enough to gain access to the sterically demanding complex 3k, deprotonating the quaternary

20 ammonium salt and leading to the cyclised molecule 4k.



Scheme 3. Isolation of intermediate 3k.


- 5 Interestingly, ammonia does not react at the ethyl-bromide side chain via a nucleophilic substitution. This is explained by the fact that the deprotonation of a quaternary amine is many orders of magnitude faster. This kinetic argument can also be applied to the intramolecular
- 10 five membered ring cyclisation, which occurs much faster compared to the intermolecular reaction pathway. Note that 3k and 4k can be oxidized by bromine to 10 and 11, respectively. Therefore, our experimental data allows us

to propose pathway A (alpha addition, cyclisation and hydride loss) as being the mechanistic pathway taken in the synthesis of the molecules of the type 6, shown in Scheme 1.

5

Pathway A is initiated by reaction of the amine with 2 via an addition at the sp^2 hybridized carbon in α position to the quaternary ammonium centre. The newly formed secondary amine 3 is then subject to a favoured 5-exo-tet cyclisation¹⁷ yielding the intermediate imidazolidine 4. Intermediate 4 is in turn subject to an oxidative process via the loss of a hydride in the presence of another equivalent of 2, which is consumed as an oxidizing agent. The isolation and characterization of the by-product 5 provides strong agreement for the last *in-situ* oxidation step. Interestingly, this process does not interfere with the purification of 6 as by-product 5 remains in solution during precipitation of the final product. Furthermore, because of the high yield obtained with each of the primary amines tested, the *in-situ* oxidation step appears to be irreversible under the reaction conditions studied. It could be suggested that the positive charge on the quaternary ammonium ion in 6 is stabilized by the mesomeric donor effect of the nitrogen from the secondary amine. This idea is supported by the X-ray crystallographic structural analysis of $[C_{23}H_{21}N_2O]Br \cdot CHCl_3$, 6a, which clearly shows the conjugation between the two nitrogen atoms.

10
15
20
25



ORTEP representation of the structure of compound 6a.

Selected bond lengths [Å]: N2-C31 1.333(3), N2-C33

1.472(3), N2-C40 1.457(3), N1-C31 1.340(3), N1-C11


5 1.389(3), N1-C32 1.475(3).

The shortening of the carbon-nitrogen bond N2-C31 compared to N2-C33 and N2-C40 indicates that it has partial double bond character and the similar bond lengths for N2-C31 and
10 C31-N1 indicates that the bonding electron density is evenly shared between these three atoms. Also, it may be hypothesized that the dihydro-imidazole component of 6 has less steric strain than the imidazolidine part of 4. Therefore, the formation of the double bond during hydride
15 loss releases steric strain in the ring. Thus, the reduction in steric strain may enhance the effectiveness of the oxidation step. Finally, during the oxidation process of 4 to 6, the central cycle regains its aromatic character and so restores conjugation between the aromatic
20 cycles a and c. To summarize, three factors appear to contribute to the effectiveness of the hydride transfer:

(i) mesomeric stabilization of the quaternary ammonium salt, (ii) relaxation of the five membered heterocyclic ring upon formation of a double bond and (iii) the
25 rearomatisation of heterocycle b enhancing the conjugation of the system.

To examine the application of the reaction to other aromatic systems, the synthesis of an already existing framework, in this case 2,3-dihydro-1*H*-imidazo[1,2-
a]quinolinium bromide derivative was investigated from 2-
5 bromo-ethyl-quinolinium bromide, 12, as a precursor
(Scheme 4). By employing an identical procedure, product
13 was isolated in a 70 % yield. The success of this
reaction demonstrates that the quinolinium framework is
also amenable to this type of methodology.

10




Scheme 4. Cascade reaction with the quinolinium
15 derivative.

In conclusion, we have developed an innovative type of
reaction that yields heteroaromatic cations and appears to
be general and effective. It is remarkable that the
20 simple reaction system described here allows facile
formation of a new subset of phenanthridinium heterocycle.
Such molecules are interesting to develop new types of DNA
intercalating framework and the cascade reaction will find
utility in organic synthesis. Notably, the observation
25 and elucidation of the spontaneous reaction sequence -
alpha addition, cyclisation and hydride loss - is
unprecedented.


Secondary Amines

The non-SN₁ non-SN₂ mechanism of 2-bromo-ethyl-phenanthridinium with secondary amine.

- 5 Reaction of 2-bromo-ethyl-phenanthridinium (2) with secondary amines in our redox condition leads to the substitution product (14):




- 10 At first sight, it looks like a usual SN₂ mechanism but we have demonstrated that it is not. Two mechanisms can explain the formation of the secondary substitution product (14):




15

With the help of the phase transfer reaction, we have seen that any nucleophile reacts on 2-bromo-ethyl-phenanthridinium (2) via a first steep alpha addition. Therefore, the first intermediate could be:


20




The following piperidine alpha-adduct and (4-Methoxy-phenyl)-methanethiol alpha-adduct were isolated in CDCl_3 solution of an NMR tube:



Like with primary amine, in a polar solvent like DMF, this first intermediate should undertake a rapid 5-exo-tet-cyclisation to yield a second intermediate:




Next, should happen a 5-membered ring oxidative re-opening:



5

To test this last hypothesis we have protonated one intermediate of the primary amine reaction:




10

Upon protonation, a ring opening occurs leading to re-aromatisation. The re-aromatisation being the driving force. Therefore, we are confident in stating that the mechanism of the reaction with secondary amine is not a usual SN₂ mechanism, but rather a "non-SN₁ non-SN₂ substitution" involving an intramolecular


15

rearrangement:












Thio-compound should follow the same mechanism:

5



Molecules obtained via the non SN_1 non SN_2 mechanism:

 + Nucleophile	Product	Yield (%)
 Piperidine	 14a	71
 Piperazine	 14b	73
 1,5,9-triaza-Cyclododecane	 14c	93
 Paramethoxybenzyl Mercaptan	 15	76

A notable advantage of this non-SN₁ non-SN₂ mechanism over
 5 a conventional substitution reaction lay in the more
 reactivity of the first conditions. A usual substitution
 on the 2-bromo-ethyl side chain would require more
 energetic conditions. Even aromatic primary amines do the
 first alpha addition at r.t. Likewise, secondary amines
 10 start the first alpha addition step in mild condition and

lead, after rearrangement, to the final substituted product.

Instrumentation and Materials

- 5 All reactions were carried out using oven-dried glassware under a nitrogen atmosphere using standard Schlenk techniques. Commercial starting materials and solvents were used as supplied, without further purification.
- 10 ^1H NMR and ^{13}C NMR were recorded using a Bruker DPX 400 spectrometer operating at 400 and 100 MHz, respectively. Chemical shifts (δ) are given in ppm relative to residual solvent peak. Coupling constants (J) are given in Hz. The multiplicities are expressed as follows: s = singlet, d =
- 15 doublet, t = triplet, q = quartet. Infra-red spectral analysis were performed on a JASCO 410 spectrophotometer, using a KBr disc unless otherwise stated; peaks are quoted in wave numbers (cm^{-1}) and their relative intensity are reported as follows: s = strong, m = medium, w = weak.
- 20 Mass spectra were obtained using a JEOL JMS 700 spectrometer operating, in FAB, EI, CI or ES mode. Microanalyses were performed on a CE-440 elemental analyzer. Melting points were determined on a digital IA9000 series melting point apparatus, using capillary
- 25 tubes.

Definitions of abbreviations


DMF = Dimethylformamide; TEA = Triethylamine; DCM = Dichloromethane; r.t. = Room temperature.

30

Preparation and physical data of the molecules

Formula A compounds


1. Preparation of 2-Bromo-ethyl-phenanthridinium bromide (2):



Phenanthridine (5.44g; 30.4 mmol) was dissolved in 1,2-Dibromoethane (114.2g; 52 ml; 608 mmol) and stirred at 110°C for three days. During that time, a white precipitate was formed and was filtered off every 12 hours. After each filtration, the filtrate was rinsed with an additional 5 ml of 1,2-Dibromoethane and the mother liquor was stirred at 90°C until the next filtration. The reaction was complete after ca. three days when no more precipitate formed. The filtrates were combined and washed thoroughly with ether and with ethyl acetate to give 2 (7.92g; 21.6 mmol) as a beige powder in a 95 % yield; mp: 234-235°C (dec.); ¹H NMR (D₂O, 400MHz): δ 9.81 (s, 1H), 8.72 (d, 1H, J=7.2 Hz), 8.63 (d, 1H, J=7.2 Hz), 8.37 (d, 1H, J=7.2 Hz), 8.26 (d, 1H, J=7.2 Hz), 8.18 (t, 1H, J=7.2 Hz), 7.98 (t, 1H, J=7.2 Hz), 7.90 (m, 2H), 5.37 (t, 2H, J=5.8 Hz), 4.05 (t, 2H, J=5.8 Hz); ¹³C NMR (D₂O, 100MHz): δ 155.27 (CH), 139.03 (CH), 135.59 (C), 133.18 (CH), 132.78 (C), 132.58 (CH), 130.85 (CH), 130.72 (CH), 126.57 (C), 125.13 (CH), 123.32 (C), 123.00 (CH), 118.91 (CH), 58.87 (CH₂), 29.41 (CH₂); IR (KBr, cm⁻¹): 2947(w), 1620(m), 763(s), 717(m); MS (ES): 288.1 (M-Br) (100), 206.2 (8); Anal. Calcd for C₁₅H₁₃NBr₂: C, 49.32; H, 3.59; N, 3.84. Found: C, 49.15; H, 3.48; N, 3.76.


30

2. Isolation and characterisation of 5-(2-Bromo-ethyl)-5,6-dihydro-phenanthridine (5):



5 During the preparation of 6a, the mother liquor from the DMF/ether (25:75) solution was kept and washed thoroughly 4 times with 40 ml of water. The organic layer was then washed with brine and dried over MgSO_4 . The solvent was evaporated down to a dark residue. Column chromatography
 10 (Silica, DCM as elutant) afforded 5 (140 mg; 0.485 mmol) as a beige powder in a 50 % yield. $R_f = 0.75$ in 100% ethyl acetate; mp: 99–100°C; $^1\text{H NMR}$ (CDCl_3 , 400MHz): δ 7.64 (d, 1H, $J=7.60$ Hz), 7.60 (d, 1H, $J=7.60$ Hz), 7.22 (t, 1H, $J=7.60$ Hz), 7.13 (t, 2H, $J=7.60$ Hz), 7.01 (d, 1H, $J=7.60$ Hz),
 15 Hz), 6.77 (t, 1H, $J=7.60$ Hz), 6.62 (d, 1H, $J=7.60$ Hz), 4.27 (s, 2H), 3.64 (t, 2H, $J=7.80$ Hz), 3.44 (t, 2H, $J=7.80$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , 100MHz): δ 145.02 (C), 132.71 (C), 132.19 (C), 129.68 (CH), 128.55 (CH), 128.22 (CH), 125.96 (CH), 124.44 (CH), 124.22 (C), 123.59 (CH), 119.19 (CH),
 20 112.51 (CH), 53.38 (CH_2), 53.26 (CH_2), 27.78 (CH_2); IR (KBr, cm^{-1}): 3429 (s), 2924 (w), 1716 (w), 1628 (s), 1601 (s), 1525 (w), 1493 (s), 1442 (s), 1340 (m), 1290 (m), 1269 (s), 1196 (s), 1022 (m), 758 (s), 725 (m), 615 (m); MS (FAB): 289 (M^+H) (100), 222.1 (7), 194.1 (35), 180.1
 25 (22), 166.1 (6), 152.1 (4), 107.2 (2), 85.7 (1), 58.1 (7); Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{NBr}$: C, 62.51; H, 4.89; N, 4.86. Found: C, 62.30; H, 4.96; N, 4.75.

3. Preparation and characterisation of 1-Isopropyl-1, 2, 3, 12b-tetrahydro-imidazo[1,2-f]phenanthridine (4d):



5


In an NMR tube, compound 2 (10 mg; 0.027 mmol) was dissolved in D_2O (0.6 ml). $CDCl_3$ (0.6 ml) was added followed by isopropylamine (2.3 μ l; 1.60 mg; 0.027 mmol) used as a reactant and as a base. The NMR tube was shaken energetically for 1 minute to allow the phase transfer process to occur. 1H and ^{13}C NMR spectra were taken of the $CDCl_3$ layer and the organic layer was then isolated for MS and IR analysis; this *in situ* NMR experiment was required as attempts to scale up the reaction were unsuccessful due to the highly unstable nature of the molecule 4d to oxidation. 1H NMR ($CDCl_3$, 400MHz): δ 7.77 (d, 1H, $J=7.8$ Hz), 7.74 (d, 1H, $J=7.2$ Hz), 7.47 (d, 1H, $J=6.4$ Hz), 7.35 (m, 2H), 7.25 (d, 1H, $J=7.6$ Hz), 6.92 (t, 1H, $J=7.6$ Hz), 6.73 (d, 1H, $J=7.8$ Hz), 4.73 (s, 1H), 3.47 (m, 1H), 3.25 (m, 4H), 1.25 (d, 3H, $J=6.4$ Hz), 1.12 (d, 3H, $J=6.4$ Hz); ^{13}C NMR ($CDCl_3$, 100MHz): δ 144.34 (C), 135.76 (C), 132.00 (C), 129.34 (CH), 127.88 (CH), 127.66 (CH), 124.13 (CH), 123.85 (CH), 123.39 (C), 123.32 (CH), 119.07 (CH), 113.45 (CH), 76.72 (CH), 51.68 (CH), 46.86 (CH_2), 45.07 (CH_2), 22.63 (CH_3), 17.21 (CH_3); Solution IR with KBr windows (cm^{-1}): 3680 (m), 3022 (s), 2968 (w), 2436 (w), 2398 (s), 1602 (w), 1522 (m), 1480 (m), 1426 (m), 1387 (w), 1136 (w), 1219 (s); MS (CI): 265.2 ($M+1$) (20), 195.1 (5), 180.1 (12), 127.1 (10), 119.1 (32), 102.2 (22), 89.1 (100).

30

4. General procedure for the preparation of 2,3-Dihydro-1H-imidazo[1,2-f]phenanthridinium bromide derivatives (6a-k):

2-Bromo-ethyl-phenanthridinium bromide (2) (700 mg; 1.9 mmol) was suspended in DMF (20 ml). Primary amine (0.95 mmol) and TEA (795 μ l; 5.7 mmol) were added successively to the stirred solution. After stirring for 48 hours at r.t. under nitrogen the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (100 ml), and this was recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to remove the TEA salt, yielding the 2,3-Dihydro-1H-imidazo[1,2-f]phenanthridinium bromide derivative (6a-j). In some rare cases the product was purified further by recrystallisation from methanol/ethyl acetate (50:50).

a. 1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide (6a):




20

6a (380 mg; 0.9 mmol) was obtained as an off white powder in a 95 % yield; mp: 245-246°C (dec.); ¹H NMR (CDCl₃, 400MHz): δ 8.52 (d, 1H, $J=8.2$ Hz), 8.36 (d, 1H, $J=8.2$ Hz), 8.21 (d, 1H, $J=8.2$ Hz), 7.93 (t, 1H, $J=8.2$ Hz), 7.69 (t, 1H, $J=8.2$ Hz), 7.56 (t, 1H, $J=8.2$ Hz), 7.51 (m, 2H), 7.32 (d, 2H, $J=8.2$ Hz), 6.91 (d, 2H, $J=8.2$ Hz), 5.41 (s, 2H),

5.04 (t, 2H, $J=10.6$ Hz), 4.68 (t, 2H, $J=10.6$ Hz), 3.76 (s, 3H); ^{13}C NMR (CDCl_3 , 100MHz): δ 160.26 (C), 154.91 (C), 136.30 (C), 135.79 (CH), 133.25 (C), 132.25 (CH), 129.49 (CH), 128.34 (CH), 127.94 (CH), 126.28 (CH), 125.29 (C), 124.42 (CH), 123.96 (CH), 120.93 (C), 116.38 (CH), 115.91 (C), 115.40 (CH), 55.81 (CH_3), 55.36 (CH_2), 52.54 (CH_2), 47.72 (CH_2); IR (KBr, cm^{-1}): 3431(s), 2924(w), 2360(w), 1612(s), 1576(s), 1514(m), 1456(m), 1304(m), 1248(m), 1026(m), 814(m), 754(m); MS (FAB): 341.2 (M-Br) (35), 232 (10), 157.1 (56), 121.2 (13), 79.7 (100); Anal. Calcd for $\text{C}_{23}\text{H}_{21}\text{N}_2\text{OBr} \cdot 0.5 \text{ H}_2\text{O}$: C, 64.19; H, 5.15; N, 6.51. Found: C, 64.87; H, 5.47; N, 6.95.

b. 1-(2-Hydroxy-ethyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide (6b):




6b (320 mg; 0.93 mmol) was obtained as a pale yellow crystalline solid in a 98 % yield; mp: 270-271°C (dec.); ^1H NMR (D_2O , 400MHz): δ 8.23 (d, 2H, $J=8.2$ Hz), 8.11 (d, 1H, $J=8.2$ Hz), 7.86 (t, 1H, $J=8.2$ Hz), 7.64 (t, 2H, $J=8.2$ Hz), 7.43 (t, 1H, $J=8.2$ Hz), 7.20 (d, 1H, $J=8.2$ Hz), 4.35 (t, 2H, $J=11$ Hz), 4.22 (t, 2H, $J=11$ Hz), 4.09 (t, 2H, $J=5.2$ Hz), 4.03 (t, 2H, $J=5.2$ Hz); ^{13}C NMR (D_2O , 100MHz): δ 153.47 (C), 135.59 (CH), 134.59 (C), 132.13 (C), 131.63 (CH), 129.30 (CH), 127.68 (CH), 125.67 (CH), 123.63 (CH), 123.29 (CH), 119.59 (C), 115.42 (CH), 114.73 (C), 59.10 (CH_2), 52.54 (CH_2), 51.45 (CH_2), 45.80 (CH_2); IR (KBr, cm^{-1}): 3433 (s), 2922 (w), 2360 (w), 1603 (s), 1576 (s), 1520 (w), 1456 (m), 1387 (w), 1302 (m), 1265 (m), 1084 (m), 874

(w), 758 (m); MS (FAB): 265.2 (M-Br) (100), 219.1 (12), 178.1 (5), 154.1 (2), 136.1 (2); Anal. Calcd for $C_{17}H_{17}N_2OBr$: C, 59.14; H, 4.96; N, 8.11; Found: C, 58.67; H, 4.78; N, 7.92.

5

c. 2,3-Dihydro-1*H*-imidazo[1,2-*f*]phenanthridin-4-ylum bromide (6c):




* NH_3 solution in water (35%)

10 6c (250 mg; 0.83 mmol) was obtained as a yellow powder in a 61 % yield; mp: 392-394 °C (dec.); 1H NMR (D_2O , 400MHz): δ 7.83 (d, 1H, $J=8.0$ Hz), 7.79 (d, 1H, $J=8.0$ Hz), 7.66 (t, 1H, $J=8.0$ Hz), 7.46 (m, 3H), 7.28 (t, 1H, $J=8.0$ Hz), 6.93 (d, 1H, $J=8.0$ Hz), 4.13 (t, 2H, $J=10.8$ Hz), 3.91 (t, 2H, $J=10.8$ Hz); ^{13}C NMR (D_2O , 100MHz): δ 154.69 (C), 135.75 (CH), 133.18 (C), 131.65 (C), 129.56 (CH), 126.26 (CH), 125.65 (CH), 123.40 (CH), 123.01 (CH), 119.25 (C), 115.45 (CH), 113.64 (C), 47.62 (CH_2), 43.04 (CH_2); IR (KBr, cm^{-1}): 3435 (s), 3028 (m), 2997 (m), 2950 (m), 2773 (w), 2684 (w), 2050 (w), 1626 (s), 1608 (s), 1585 (s), 1469 (m), 1454 (m), 1358 (m), 1294 (m), 1267 (w), 1169 (w), 1022 (w), 754 (s); MS (EI+): 220 (M-Br) (10), 219.3 (12), 142.3 (8), 112.2 (5), 100.2 (15), 86.2 (100), 56.1 (50); Anal. Calcd for $C_{15}H_{13}N_2Br$: C, 59.82; H, 4.35; N, 9.30; Found: C, 59.39; H, 4.23; N, 9.03.

25


d. 1-Isopropyl-2,3-dihydro-1*H*-imidazo[1,2-*f*]phenanthridin-4-ylum (6d):



6d (267 mg; 0.78 mmol) was obtained as a yellow powder in a 82 % yield; mp: 250-251°C (dec.); ¹H NMR (CD₃OD, 400MHz): δ 8.81 (d, 1H, J=8.4 Hz), 8.62 (d, 1H, J=8.4 Hz), 8.58 (d, 1H, J=8.4 Hz), 8.12 (t, 1H, J=8.4 Hz), 7.90 (t, 1H, J=8.4 Hz), 7.82 (t, 1H, J=8.4 Hz), 7.62 (m, 2H), 5.23 (q, 1H, J=6.6 Hz), 4.76 (t, 2H, J=10.5 Hz), 4.38 (t, 2H, J=10.5 Hz), 1.62 (d, 6H, J=6.6 Hz); ¹³C NMR (CD₃OD, 100MHz): δ 155.03 (C), 137.64 (C), 136.76 (CH), 134.96 (C), 133.02 (CH), 130.74 (CH), 129.55 (CH), 126.95 (CH), 125.81 (CH), 125.29 (CH), 122.21 (C), 117.52 (C), 116.98 (CH), 52.50 (CH), 47.51 (CH), 45.16 (CH₂), 21.22 (CH₃); IR (KBr, cm⁻¹): 3433(s), 2981(w), 2015(w), 1610(m), 1597(m), 1574(s), 1550(s), 1556(w), 1303(m), 1169(w), 1126(w), 1068(w), 758(m); MS (FAB): 263.2 (M-Br) (100), 221.1 (6), 154.1 (12), 137.1 (6), 89.6 (2), 77.7 (1); Anal. Calcd for C₁₈H₁₉N₂Br · 0.25 H₂O: C, 62.17; H, 5.65; N, 8.90; Found: C, 62.27; H, 6.01; N, 8.95.

20

e. 1-Cyclopropyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide (6e):



6e (250 mg; 0.74 mmol) was obtained as a white off powder in a 78 % yield; mp: 129-130°C (dec.); ¹H NMR (D₂O,


25

400MHz): δ 8.84 (d, 1H, $J=8.4$ Hz), 8.20 (d, 1H, $J=8.0$ Hz),
8.84 (d, 1H, $J=8.0$ Hz), 8.10 (d, 1H, $J=8.0$ Hz), 7.85 (t,
1H, $J=8.0$ Hz), 7.64 (m, 2H), 7.42 (t, 1H, $J=8.0$ Hz), 7.17
(d, 2H, $J=8.0$ Hz), 4.25 (t, 2H, $J=11$ Hz), 4.11 (t, 2H,
5 $J=11$ Hz), 3.26 (qt, 1H, $J=3.5$ Hz), 1.21 (m, 2H), 1.03 (m,
2H); ^{13}C NMR (D_2O , 100MHz): δ 155.05 (C), 155.05 (C),
135.52 (CH), 134.87 (C), 132.43 (C), 131.55 (CH), 129.24
(CH), 128.88 (CH), 125.69 (CH), 123.55 (CH), 123.40 (CH),
119.98 (C), 115.46 (CH), 102.52 (C), 49.95 (CH_2), 45.77
10 (CH_2), 31.51 (CH), 10.49 (2^*CH_2); IR (KBr, cm^{-1}): 3427(s),
3024(w), 2358(w), 1610(m), 1595(m), 1575(s), 1548(s),
1454(m), 1356(w), 1307(m), 1045(w), 762(m); MS (FAB):
261.1 (M-Br) (100), 219.1 (6), 154 (12), 136 (11), 120.1
(2), 89.5 (2), 77.7(1); Anal. Calcd for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{Br}$: C,
15 64.35; H, 5.02; N, 8.21. Found: C, 64.68; H, 5.02; N,
8.09.

f. L-alanine methoxycarbonyl derivative (6f):


6f (550 mg; 1.2 mmol) was obtained as a hygroscopic white
20 powder in a 63 % yield; 137-138 °C; ^1H NMR (D_2O , 400MHz):
 δ 8.13 (d, 1H, $J=8.0$ Hz), 8.03 (d, 1H, $J=8.0$ Hz), 7.87 (d,
1H, $J=8.0$ Hz), 7.82 (t, 1H, $J=8.0$ Hz), 7.62 (t, 1H, $J=8.0$
Hz), 7.59 (t, 1H, $J=8.0$ Hz), 7.44 (t, 1H, $J=8.0$ Hz), 7.22
(d, 1H, $J=8.0$ Hz), 7.05 (d, 2H, $J=6.4$ Hz), 6.82 (m, 3H),
25 5.90 (dd, 1H, $J=15.6$ and 4 Hz), 4.48 (m, 1H), 4.30 (m,
2H), 4.19 (m, 1H), 3.84 (s, 3H), 3.50 (dd, 1H, $J=15.6$ and
4 Hz), 3.24 (dd, 1H, $J=15.6$ and 11.2 Hz); ^{13}C NMR (D_2O ,
100MHz): δ 135.96 (CH), 135.10 (C), 135.05 (C), 131.72
(CH), 131.5 (C), 129.22 (CH), 129.00 (CH), 127.80 (CH),
30 127.01 (CH), 126.64 (CH), 124.06 (CH), 123.51 (CH), 121.00
(CH), 120.00 (C), 115.97 (CH), 114.6 (C); MS (FAB): 383.5
(M-Br) (100), 307.3 (12), 233.2 (5), 219.2 (5), 154.1
(22), 137.1 (15); Anal. Calcd for $\text{C}_{25}\text{H}_{23}\text{BrN}_2\text{O}_2$: C, 64.80; H,
5.00; Br, 17.24; N, 6.05; O, 6.91.

g. Ethylene diamine derivative (6g):




5
 2-Bromo-ethyl-phenanthridinium bromide (2) (700 mg; 1.9 mmol) was suspended in DMF (20 ml). Ethylenediamine (31.8 μl ; 0.48 mmol) and TEA (795 μl ; 5.7 mmol) were added successively to the stirred solution. After stirring for
 10 48 hours at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (100 ml) and recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to
 15 remove the TEA salt, yielding 6g (295 mg; 0.47 mmol) as a yellow powder in a 98 % yield; mp: > 400°C; ^1H NMR ((CD_3) $_2\text{SO}$, 400MHz): δ 8.70 (d, 2H, $J=8.0$ Hz), 8.66 (d, 2H, $J=8.0$ Hz), 8.62 (d, 2H, $J=8.0$ Hz), 8.01 (t, 2H, $J=8.0$ Hz), 7.87 (t, 2H, $J=8.0$ Hz), 7.78 (t, 2H, $J=8.0$ Hz), 7.66 (m,
 20 4H), 4.76 (s, 4H), 4.68 (t, 4H, $J=10.6$ Hz), 4.50 (t, 4H, $J=10.6$ Hz); IR (KBr, cm^{-1}): 3435 (s), 1612 (m), 1597 (m), 1574 (s), 1554 (s), 1456 (w), 1311 (m), 1265 (m), 762 (m); MS (FAB): 234 ((M-2Br)/2) (5), 232 (10), 214 (5), 198 (1), 157 (35), 137 (5), 102.4 (2), 79.6 (100), 61.8 (5); Anal.
 25 Calcd for $\text{C}_{32}\text{H}_{28}\text{N}_4\text{Br}_2 \cdot \text{H}_2\text{O}$: C, 59.46; H, 4.68; N, 8.67.
 Found: C, 59.80; H, 4.42; N, 8.31.

h. Tris(2-aminoethyl)amine derivative (6h):



2-Bromo-ethyl-phenanthridinium bromide (2) (1g; 2.72 mmol) was suspended in DMF (50 ml). Tris(2-aminoethyl)amine (68 μl ; 0.454 mmol) and TEA (1.15 ml; 8.2 mmol) were added successively to the stirred solution. After stirring for 48 hours at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (100 ml) and recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to removed the TEA salt, yielding 6h (430 mg; 0.43 mmol) as a yellow powder in a 95 % yield; mp: 326-327°C; ^1H NMR ((CD_3) $_2\text{SO}$, 400MHz): δ 8.61 (d, 3H, $J=8.0$ Hz), 8.51 (d, 3H, $J=8.0$ Hz), 8.43 (d, 3H, $J=8.0$ Hz), 7.94 (t, 3H, $J=8.0$ Hz), 7.82 (m, 6H), 7.57 (t, 3H, $J=8.0$ Hz), 7.51 (d, 3H, $J=8.0$ Hz), 4.57 (t, 6H, $J=10.0$ Hz), 4.44 (t, 6H, $J=10.0$ Hz), 4.35 (m, 6H), 3.35 (m, 6H); ^{13}C NMR ((CD_3) $_2\text{SO}$, 100MHz): δ 153.55 (C), 135.43 (C), 134.81 (CH), 132.72 (C), 131.78 (CH), 129.50 (CH), 127.69 (CH), 125.67 (CH), 124.31 (CH), 124.08 (CH), 119.79 (C), 116.09 (C), 115.25 (CH), 51.76 (CH_2), 51.46 (CH_2), 49.19 (CH_2), 46.25 (CH_2); IR (KBr, cm^{-1}): 3435 (s), 2925 (w), 2358 (w), 1610 (s), 1575 (s), 1456 (m), 1384 (w), 1304 (m), 1267 (m), 1106 (w), 750 (w), 717 (w), 667 (w); Anal. Calcd for $\text{C}_{51}\text{H}_{48}\text{Br}_3\text{N}_7$: C, 61.34; H, 4.84; N, 9.82; Found: C, 61.11; H, 4.90; N, 9.62.


i. **cis-1,3,5-Triaminocyclohexane derivative (6i):**



2-Bromo-ethyl-phenanthridinium bromide (2) (1g; 2.72 mmol) was suspended in DMF (30 ml). Cis-1, 3, 5-Triaminocyclohexane (58 mg; 0.45 mmol) and TEA (1.15 ml; 8.16 mmol) were added successively to the stirred solution. After stirring for 48 hours at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (100 ml) and recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to removed the TEA salt, yielding 6i (400 mg; 0.41 mmol) as a yellow powder in a 91 % yield; mp: 360 °C (dec.); ¹H NMR ((CD₃)₂SO, 400MHz): δ 9.11 (d, 3H, J=8.4 Hz), 8.91 (d, 3H, J=8.4 Hz), 8.73 (d, 3H, J=8.0 Hz), 8.18 (t, 3H, J=5.1 Hz), 8.04 (t, 3H, J=5.1 Hz), 7.86 (t, 3H, J=5.1 Hz), 7.70 (d, 3H, J=8.0 Hz), 7.64 (t, 3H, J=5.1 Hz), 5.93 (m, 3H), 4.79 (t, 6H, J=6.9 Hz), 4.53 (t, 6H, J=6.9 Hz), 2.82 (q, 3H, J=11.6 Hz), 2.6 (d, 3H, J=11.6 Hz); ¹³C NMR ((CD₃)₂SO, 100MHz): δ 156.31 (CH), 135.53 (CH), 135.25 (C), 133.11 (CH), 131.82 (CH), 130.40 (CH), 129.17 (CH), 125.80 (C), 124.68 (CH), 124.23 (C), 120.41 (CH), 116.32 (C), 115.85 (CH), 52.66 (CH₂), 46.25 (CH₂), 45.54 (CH), 32.43 (CH₂); IR (KBr, cm⁻¹): 3421 (s), 1610 (s), 1570 (s), 1533 (s), 1452 (m), 1386 (w), 1304


(s), 1263 (s), 1155 (m), 1122 (m), 783 (m), 754 (s), 717 (m), 669 (m); MS (FAB): 247.14 ((M-3*Br)/3) (5), 232.1 (11), 219.11 (10), 214.08 (2), 157.1 (45), 79.7 (100); Anal. Calcd for C₅₁H₄₅Br₃N₆: C, 62.40; H, 4.62; N, 8.56; Found: C, 62.30; H, 4.71; N, 8.64.

j. 1-(4-Methoxy-phenyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide (6j):



6j (285 mg; 0.7 mmol) was obtained as a pale green powder in a 74 % yield; mp: 368-369°C (dec.); ¹H NMR ((CD₃)₂SO, 400MHz): δ 8.90 (d, 1H, J=8.0 Hz), 8.80 (d, 1H, J=8.0 Hz), .05 (t, 1H, J=8.0 Hz), 7.91 (t, 1H, J=8.0 Hz), 7.82 (d, 1H, J=8.0 Hz), 7.67 (m, 3H), 7.58 (t, 1H, J=8.0 Hz), 7.35 (d, 1H, J=8.0 Hz), 7.24 (d, 2H, J=8.0 Hz), 4.92 (t, 2H, J=9.8 Hz), 4.56 (t, 2H, J=9.8 Hz), 3.88 (s, 3H); ¹³C NMR ((CD₃)₂SO, 100MHz): δ 160.42 (C), 152.98 (C), 135.59 (CH), 135.36 (C), 133.03 (C), 131.90 (CH), 131.88 (CH), 129.02 (CH), 128.51 (CH), 128.50 (CH), 127.29 (CH), 125.98 (CH), 124.64 (CH), 124.43 (CH), 120.63 (C), 120.62 (C), 116.45 (CH), 116.30 (CH), 115.77 (C), 56.02 (CH₃), 55.01 (CH₂), 47.09 (CH₂); IR (KBr, cm⁻¹): 3435(s), 29232(w), 2360(w), 1610(s), 1577(s), 1554(m), 1512(m), 1456(w), 1298(w), 1251(s), 1028(m), 764(m); MS (FAB): 327.1 (M-Br) (100), 307.1 (20), 289.1 (10), 261.1 (2), 219.1 (2), 154 (80), 136 (50), 107.3 (16), 89.5 (14), 77.6 (12), 65.8 (5), 52 (5); Anal. Calcd for C₂₂H₁₉N₂OBr · H₂O: C, 62.13; H, 4.98; N, 6.59. Found: C, 62.21; H, 4.46; N, 6.60.

k. 1-Phenyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylum bromide (6k):



5 6k (260 mg; 0.695 mol) was obtained as a yellow powder in a 73 % yield; mp: 355-356°C (dec.); ¹H NMR (CD₃OD, 400MHz): δ 8.85 (d, 1H, J=8.4 Hz), 8.75 (d, 1H, J=8.4 Hz), 8.05 (t, 1H, J=8.4 Hz), 7.93 (t, 1H, J=8.4 Hz), 7.81 (d, 1H, J=8.4 Hz), 7.71 (m, 6H), 7.45 (m, 2H), 5.04 (t, 2H, J=10.4 Hz), 4.69 (t, 2H, J=10.4 Hz); ¹³C NMR (CD₃OD, 100MHz): δ 154.87 (C), 144.05 (C), 141.02 (CH), 137.69 (CH), 137.07 (CH), 134.63 (C), 133.20 (CH), 132.60 (CH), 132.02 (CH), 129.94 (CH), 129.24 (CH), 128.47 (CH), 126.45 (CH), 125.76 (CH), 122.72 (C), 120.46 (C), 117.43 (CH), 117.00 (C), 56.19 (CH₂), 48.76 (CH₂); IR (KBr, cm⁻¹): 3434 (s), 3047 (w), 1612 (m), 1599 (m), 1575 (s), 1545 (s), 1485 (w), 1440 (m), 1309 (s), 1171 (w), 935 (w), 758 (s); MS (FAB): 297 (M-Br) (100), 269 (2), 230 (8), 219 (4), 178 (4), 154 (6), 136 (5), 107.2 (1), 77.6 (2); Anal. Calcd for C₂₁H₁₇N₂Br · 0.5H₂O: C, 65.30; H, 4.70; N, 7.25. Found: C, 65.71; H, 4.53; N, 7.11.

Alternative Synthesis of Compounds Represented by Formula

A

25 In an alternative method for producing the compounds of the invention an oxidizing agent, such as N-bromo-succinimide, was used to avoid the consumption of an equivalent of the phenanthridinium starting material, and a biphasic solution of water/ethyl acetate was employed to

facilitate the isolation of the non-oxidized 5-membered ring as well as the elimination of the base and its HBr salt. A solution of triethanolamine (557 μ l; 4 mmol), Sodium hydrogen carbonate (3g; 35.7 mmol) and primary amine (2.1 mmol) in ethyl acetate (40 ml) and water (40 ml) was prepared in a round bottom flask. 2-Bromo-ethyl-Phenanthridinium (700 mg; 1.9 mmol) was added under nitrogen to the stirred solution at 0°C. The solution was left stirring and warming-up to r.t., under nitrogen, for 2H. The organic layer was separated, washed three times with water and placed into a round bottom flask cover with aluminium foil. N-Bromosuccinimide (373.8 mg; 2.1 mmol) was added to the stirred solution at 0°C and the reaction mixture was left stirring and warming-up to r.t, overnight, in the dark. The final product precipitated from the solution was removed by filtration and washed with diethyl ether to yield the corresponding DIP framework.

20 Formula B compounds

1. Preparation of 5-(2-Piperidin-1-yl-ethyl)-phenanthridinium bromide 14a:

2-Bromo-ethyl-phenanthridinium bromide (700 mg; 1.9 mmol) was dissolved in 20 ml DMF. Piperidine (179 mg; 208 μ l; 2.1 mmol) and TEA (0.576 mg; 795 μ l; 5.7 mmol) were added successively to the stirred solution. After stirring for 48H at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (50 ml) and this was recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to get ride of the TEA salt to obtain 14a (500 mg; 1.35 mmol) as a pale yellow powder in a 71 % yield; mp: 167-168°C; ^1H NMR (D_2O , 400MHz): δ 9.80 (s, 1H), 8.90

(d, 1H, J=7.2 Hz), 8.83 (d, 1H, J=8.4 Hz), 8.41 (d, 1H, J=8 Hz), 8.28 (m, 2H), 7.99 (m, 3H), 5.15 (t, 2H, J=7.2 Hz), 3.04 (t, 2H, J=7.2 Hz), 2.56 (m, 4H), 1.50 (m, 4H), 1.41 (m, 2H); ¹³C NMR (D₂O, 100MHz): δ 154.63 (CH), 147.71 (C), 138.61 (CH), 136.45 (C), 135.35 (C), 132.72 (CH), 132.47 (CH), 130.67 (CH), 126.56 (CH), 125.11 (CH), 123.83 (C), 123.04 (CH), 119.06 (CH), 56.40 (CH₂), 54.87 (CH₂), 54.18 (CH₂), 25.11 (CH₂), 23.42 (CH₂); IR (KBr, cm⁻¹): 3448 (s), 2923 (m), 2852 (w), 2794 (w), 2360 (w), 1628 (s), 1535 (w), 1506 (w), 1454 (m), 1352 (w), 1257 (w), 1161 (w), 1122 (w), 1036 (w), 769 (s); MS (FAB): 291.2 (M-Br) (100); 273.1 (4), 206.1 (7), 193 (7), 154 (92), 137 (60), 136 (60), 112.3 (45), 98.4 (16), 89.5 (11), 77.6 (5), 56.9 (2), 52 (2); Anal. Calcd for C₂₀H₂₃N₂Br: C, 64.69; H, 6.24; N, 7.54. Found: C, 64.17; H, 6.10; N, 7.58.

2. Preparation of Piperazine derivative 14b:

2-Bromo-ethyl-phenanthridinium bromide (700 mg; 1.9 mmol) was dissolved in 20 ml DMF. Piperazine (81.8 mg; 0.95 mmol) and TEA (0.576 mg; 795 μl; 5.7 mmol) were added successively to the stirred solution. After stirring for 48H at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (50 ml) and this was recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to get rid of the TEA salt to obtain 14b (450 mg; 0.7 mmol) as a yellow powder in a 73 % yield; mp: 260-261°C; ¹H NMR (D₂O, 400MHz): δ 9.80 (s, 2H), δ 8.95 (d, 2H, J=8.0 Hz), δ 8.88 (d, 2H, J=8.0 Hz), δ 8.42 (d, 2H, J=8.0 Hz), δ 8.33 (d, 2H, J=8.0 Hz), δ 8.29 (t, 2H, J=8.0 Hz), δ 8.01 (m, 6H), δ 5.14 (t, 4H, J=6.8 Hz), δ 3.05 (t, 4H, J=6.8 Hz), δ 2.57 (s, 8H); ¹³C NMR (D₂O, 100MHz): δ

155.94 (CH), δ 138.46 (CH), δ 134.63 (C), δ 133.28 (CH), δ
133.07 (C), δ 132.41 (CH), δ 130.89 (CH), δ 130.54 (CH), δ
126.03 (C), δ 125.48 (CH), δ 123.66 (CH), δ 120.19 (CH),
5 δ 55.43 (CH₂), δ 55.08 (CH₂), δ 52.95 (CH₂); IR (KBr, cm-
1): 3430.74 (s), 2923 (w), 2360 (w), 1626 (s), 1456 (m),
1261 (w), 1026 (w), 758 (w); MS (FAB): 498.4 (M-2Br) (60),
318.2 (30), 292.1 (50), 249.1 (80), 206.1 (70), 154.0
(100), 136.0 (80), 112.3 (35), 56.9 (30); Anal. Calcd for
10 C₃₄H₃₄N₄Br₂: C, 62.01; H, 5.20; N, 8.51; Found: C, 62.30;
H, 5.45; N, 8.51.

3. Preparation of the Triazacyclododecane derivative

14c:

2-Bromo-ethyl-phenanthridinium bromide (700 mg; 1.9 mmol)
15 was dissolved in 20 ml DMF. 1,5,9-triaza-Cyclododecane (108
mg; 0.63 mmol) and TEA (0.576 mg; 795 μ l; 5.7 mmol) were
added successively to the stirred solution. After stirring
for 48 h at r.t. under nitrogen, the final product and TEA
hydrobromide salt were precipitated from the solution with
20 diethyl ether (50 ml) and this was recovered by
filtration. The precipitate was washed thoroughly with
diethyl ether and ethyl acetate and then triturated with 1
ml of water to get rid of the TEA salt to obtain 14c (605
mg; 0.59 mmol) as a yellow powder in a 93 % yield; ¹H NMR
25 (CD₃OD, 400 MHz): δ 9.93 (s, 3H), 8.99 (t, 6H, J=8.8 Hz),
8.45 (d, 3H, J=8.0 Hz), 8.42 (d, 3H, J=6.8 Hz), 8.30 (t,
3H, J=7.6 Hz), 8.00 (m, 6H), 7.85 (t, 3H, J=7.6 Hz), 5.02
(m, 6H), 2.57 (m, 6H), 1.41 (m, 12H), 0.05 (m, 6H); ¹³C NMR
(CD₃OD, 100 MHz): δ 156.53 (CH), 140.11 (CH), 136.93 (C),
30 135.00 (C), 134.23 (CH), 133.95 (CH), 132.28 (CH), 132.19
(CH), 128.13 (C), 126.71 (CH), 125.14 (C), 124.85 (CH),
121.43 (CH), 57.57 (CH₂), 53.34 (CH₂), 49.39 (CH₂), 23.25
(CH₂).

4. Preparation of 5-[2-(4-Methoxy-benzylsulfanyl)-ethyl]-phenanthridinium bromide 15:

2-Bromo-ethyl-phenanthridinium bromide (700 mg; 1.9 mmol) was dissolved in 20 ml DMF. (4-Methoxy-phenyl)-methanethiol (324 mg; 208 μ l; 2.1 mmol) and TEA (0.576 mg; 795 μ l; 5.7 mmol) were added successively to the stirred solution. After stirring for 48H at r.t. under nitrogen, the final product and TEA hydrobromide salt were precipitated from the solution with diethyl ether (50 ml) and this was recovered by filtration. The precipitate was washed thoroughly with diethyl ether and ethyl acetate and then triturated with 1 ml of water to get ride of the TEA salt to obtain 9 (500 mg; 1.35 mmol) as a pale yellow powder in a 76 % yield; mp: 182-183°C; ^1H NMR (CD_3OD , 400MHz): δ 9.91 (s, 1H), δ 9.08 (t, 2H, $J=8.0$ Hz), δ 8.85 (d, 1H, $J=8.0$ Hz), δ 8.47 (t, 1H, $J=8.0$ Hz), δ 8.37 (m, 1H), δ 8.15 (t, 1H, $J=8.0$ Hz), δ 8.11 (m, 2H), δ 6.80 (d, 2H, $J=8.8$ Hz), δ 6.33 (d, 2H, $J=8.8$ Hz), δ 5.17 (t, 2H, $J=6.0$ Hz), δ 4.90 (t, 2H, $J=6.0$ Hz), δ 3.69 (s, 3H), δ 3.56 (s, 2H); ^{13}C NMR (CD_3OD , 100MHz): δ 161.8 (C), δ 156.84 (C), δ 140.00 (CH), δ 137.21 (C), δ 134.41 (CH), δ 133.77 (CH), δ 132.07 (CH), δ 131.96 (CH), δ 131.31 (C), δ 130.96 (CH), δ 128.00 (C), δ 126.72 (CH), δ 125.21 (CH), δ 124.74 (CH), δ 120.76 (CH), δ 114.96 (CH), δ 58.90 (CH_2), δ 55.92 (CH_3), δ 36.97 (CH_2), δ 31.70 (CH_2); IR (KBr, cm^{-1}): 3435 (s), 1626 (s), 1533 (w), 1510 (s), 1450 (m), 1304 (w), 1248 (s), 1174 (w), 1030 (s), 829 (s), 764 (s); MS (FAB): 360.0 (M-Br) (70), 309.0 (20), 290.0 (15), 238.0 (5), 206.0 (10), 179 (7), 155.0 (100), 136.0 (50), 121.1 (50), 108.2 (20), 89.5 (12); Anal. Calcd for $\text{C}_{23}\text{H}_{22}\text{NOSBr}$: C, 62.72; H, 5.03; N, 3.18; Found: C, 62.72; H, 5.01; N, 3.78.

5. Preparation of 5-(2-Bromo-ethyl)-6-piperidin-1-yl-5,6-dihydro-phenanthridine 16:

In an NMR tube, 2-Bromo-ethyl-phenanthridinium bromide (2) (12.8 mg; 0.035 mmol) was dissolved in D₂O (0.6 ml). A 56 mM solution of piperidine in CDCl₃ was prepared by dissolving piperidine (5.5 µl; 56 µmol) in 995 µl CDCl₃. 0.6 ml of this solution (0.034 mmol) was added to the D₂O layer and the NMR tube was energetically shaken for 1 minute to allowed the phase transfer process to occur. Piperidine is used in default to avoid a second reaction on the less electrophilic centre of (2). Piperidine is also used as a base so only half of it should undergo the alpha addition step. A ¹H NMR spectrum of the bottom CDCl₃ layer was taken, characterising (16). Note that the compound is highly unstable in solution as it undergoes intermolecular and intramolecular reactions (carbon-bromide substitution). The solution becomes yellow in minutes and the ¹H NMR spectrum becomes quickly non-interpretable. Neither mass spectroscopy nor ¹³C NMR spectrum was therefore possible to obtained. ¹H NMR (CDCl₃, 400MHz): δ 7.98 (d, 1H, J=8.8 Hz), 7.93 (d, 1H, J=8.0 Hz), 7.44 (m, 2H), 7.37 (t, 1H, J=6.2 Hz), 7.28 (d, 1H, J=7.2 Hz), 6.94 (t, 1H, J=7.2 Hz), 6.82 (d, 1H, J=8.0 Hz), 5.76 (s, 1H), 4.2 (m, 2H), 3.75 (m, 1H), 3.60 (m, 1H), 1.69 (t, 4H, J=5.6), 1.45 (m, 6H).

6. Preparation of 5-(2-Bromo-ethyl)-6-(4-methoxybenzylsulfanyl)-5,6-dihydro-phenanthridine 17:

In an NMR tube, 2-Bromo-ethyl-phenanthridinium (2) (12.6 mg; 0.034 mmol) was dissolved in D₂O (0.6 ml) and CDCl₃ (0.6 ml) was added. 4-methoxybenzyl mercaptan (4.7 µl; 0.034 mmol) was added. No reaction takes place before adding TEA as the thio-derivative is not basic enough to start the reaction. TEA (4.7 µl; 0.034 mmol) was added

and the NMR tube was energetically shaken for 1 minute to allowed the phase transfer process to occur. 4-

methoxybenzyl mercaptan is used in default to avoid a second reaction on the less electrophilic centre of (2).

5 A ^1H and ^{13}C NMR spectrum of the bottom CDCl_3 layer as well as a mass spectrum were taken, characterising 17; ^1H NMR (CDCl_3 , 400MHz): δ 7.83 (t, 2H, $J=7.2$ Hz), 7.40 (t, 1H, $J=7.2$ Hz), 7.30 (m, 2H), 7.21 (d, 1H, $J=7.6$ Hz), 7.07 (d, 2H, $J=8.8$ Hz), 6.98 (t, 1H, $J=7.4$ Hz), 6.79 (d, 2H, $J=8.8$ Hz), 6.75 (d, 1H, $J=7.6$ Hz), 5.74 (s, 1H), 4.00 (m, 1H), 3.82 (m, 1H), 3.74 (s, 3H), 3.65 (m, 2H), 3.50 (s, 2H); ^{13}C NMR (CDCl_3 , 100MHz): δ 159.80 (C), 158.32 (C), 133.12 (CH), 134.33 (CH), 132.14 (CH), 130.28 (CH), 129.75 (CH), 129.12 (C), 124.71 (CH), 122.45 (C), 122.26 (CH), 120.00 (C), 119.06 (CH), 114.06 (C), 113.91 (CH), 79.10 (CH), 56.32 (CH_2) 55.25 (CH_3), 35.38 (CH_2), 33.62 (CH_2); MS (EI+): 361.4 (M-Br) (25), 240.2 (18), 219.2 (35), 194.2 (100), 180.2 (47), 166 (25), 121.2 (58), 86.2 (18).

20 **7. Preparation of Hydrobromide salt of 5-(2-Isopropylamino-ethyl)-phenanthridinium bromide 7d:**

2-Bromo-ethyl-phenanthridinium (2) (700 mg; 1.9 mmol) was suspended in 20 ml of water and 20 ml of chloroform. To the stirred solution, was added isopropylamine (162.4 μl ; 1.9 mmol) followed by TEA (794 μl ; 5.7 mmol). The solution was left stirring at r.t. under nitrogen for 1h. The aqueous layer was removed and the organic solution was washed twice with 20 ml water to have the non-oxidized 5 membered ring intermediate (4d) in solution (1.9 mmol; 20 ml at 95 mM). 20 ml of HBr 48% was added and the solution was stirred overnight at room temperature. 30 ml of water was added to dissolve the yellow precipitate newly formed and the aqueous layer was separated and washed twice with ethyl acetate. The aqueous solution was then concentrated

under vacuum to 2 ml and precipitated by adding acetone. The precipitate was recovered by filtration and washed with ethyl acetate to yield 7d (780 mg; 1.8 mmol) as a white off powder in a 96% yield; mp: 285-286°C; ¹H NMR (D₂O, 400MHz): δ 9.96 (s, 1H), 9.00 (2, 1H, J=8.0 Hz), 8.91 (d, 1H, J=8.0 Hz), 8.48 (d, 1H, J=8.0 Hz), 8.35 (m, 2H), 8.11 (t, 1H, J=8.0 Hz), 8.07 (d, 1H, J=8.0 Hz), 8.02 (t, 1H, J=8.0 Hz), 5.44 (t, 2H, J=7.0 Hz), 3.80 (t, 2H, J=7.0 Hz), 3.45 (sept, 1H, J=6.5 Hz), 1.25 (d, 6H, J=6.5 Hz); ¹³C NMR (D₂O, 100MHz): δ 164.50 (C), 156.17 (CH), 139.47 (CH), 136.17 (C), 133.23 (CH), 132.87 (CH), 131.08 (CH), 130.93 (CH), 127.10 (C), 125.61 (CH), 124.05 (C), 123.34 (CH), 118.76 (CH), 54.17 (CH), 52.44 (CH₂), 43.04 (CH₃), 18.42 (CH₂); MS (CI⁺): 267.2 (M-2Br+H⁺) (100), 265.2 (60), 195.1 (15), 180.1 (25); Anal. Calcd for C₁₈H₂₂Br₂N₂: C, 50.13; H, 5.20; N, 6.57; Found: C, 50.20; H, 5.03; N, 6.44.

8. Alternative Method B

A 7.5 % NaHCO₃ solution (40 ml) was prepared (NaHCO₃ (3 g; 35.7 mmol) in 40 ml water) and ethyl acetate (40 ml) was added followed by TEA (557 µl; 4 mmol). The biphasic solution was cooled down to 0°C and the primary amine (2.1 mmol) was added followed by **AP2-7** (700 mg; 1.9 mmol). The reaction mixture was stirred under nitrogen at r.t. for 3 hours. The organic layer was separated, washed three times with water and placed into a round bottom flask cover with aluminium foil. N-Bromosuccinimide (373.8 mg; 2.1 mmol) was added to the stirred solution at 0°C and the reaction mixture was then stirred at r.t. for 3 hours in the dark. The final product precipitated from the solution was recovered by filtration and washed with diethyl ether to yield the corresponding DIP framework.

References:

The references mentioned herein are all expressly incorporated by reference in their entirety.

Figure 1:






Figure 2






Figure 3

